CN101980717A - 黑皮质素治疗胰岛素敏感的应用 - Google Patents
黑皮质素治疗胰岛素敏感的应用 Download PDFInfo
- Publication number
- CN101980717A CN101980717A CN2008801238931A CN200880123893A CN101980717A CN 101980717 A CN101980717 A CN 101980717A CN 2008801238931 A CN2008801238931 A CN 2008801238931A CN 200880123893 A CN200880123893 A CN 200880123893A CN 101980717 A CN101980717 A CN 101980717A
- Authority
- CN
- China
- Prior art keywords
- arg
- cys
- seq
- ala
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010022489 Insulin Resistance Diseases 0.000 title abstract description 256
- 108010008364 Melanocortins Proteins 0.000 title description 14
- 239000002865 melanocortin Substances 0.000 title description 14
- 238000011282 treatment Methods 0.000 claims abstract description 293
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 12
- 229940091173 hydantoin Drugs 0.000 claims description 338
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 335
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 181
- 150000001875 compounds Chemical class 0.000 claims description 149
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 126
- 102000004877 Insulin Human genes 0.000 claims description 63
- 108090001061 Insulin Proteins 0.000 claims description 63
- 229940125396 insulin Drugs 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 51
- 229960002870 gabapentin Drugs 0.000 claims description 24
- 230000037396 body weight Effects 0.000 claims description 22
- 206010033307 Overweight Diseases 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 13
- 230000003203 everyday effect Effects 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims description 8
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 8
- CXISPYVYMQWFLE-UHFFFAOYSA-N N-D-alanyl-glycine Natural products CC(N)C(=O)NCC(O)=O CXISPYVYMQWFLE-UHFFFAOYSA-N 0.000 claims description 6
- 108010047495 alanylglycine Proteins 0.000 claims description 6
- 210000000664 rectum Anatomy 0.000 claims description 6
- 108010050848 glycylleucine Proteins 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 108010027338 isoleucylcysteine Proteins 0.000 claims description 5
- 230000003442 weekly effect Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 102000004378 Melanocortin Receptors Human genes 0.000 abstract description 274
- 108090000950 Melanocortin Receptors Proteins 0.000 abstract description 274
- 239000003446 ligand Substances 0.000 abstract description 256
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 18
- 102000005962 receptors Human genes 0.000 abstract description 15
- 108020003175 receptors Proteins 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000004913 activation Effects 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1607
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 406
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 354
- 125000002252 acyl group Chemical group 0.000 description 250
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 184
- 229940000635 beta-alanine Drugs 0.000 description 181
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 143
- 102220369446 c.1274G>A Human genes 0.000 description 143
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 140
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 124
- 230000008034 disappearance Effects 0.000 description 103
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 98
- 125000000217 alkyl group Chemical group 0.000 description 95
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 88
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 84
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 69
- 239000000203 mixture Substances 0.000 description 55
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 53
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 44
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 44
- 125000003118 aryl group Chemical group 0.000 description 37
- 125000002769 thiazolinyl group Chemical group 0.000 description 37
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 36
- 235000004279 alanine Nutrition 0.000 description 32
- 125000000304 alkynyl group Chemical group 0.000 description 32
- -1 Gaba Chemical compound 0.000 description 31
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 27
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 27
- 125000003107 substituted aryl group Chemical group 0.000 description 26
- YPJJGMCMOHDOFZ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-3-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CSC2=C1 YPJJGMCMOHDOFZ-ZETCQYMHSA-N 0.000 description 25
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 25
- 239000002253 acid Substances 0.000 description 24
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 23
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 21
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 20
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 18
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 17
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 17
- 229960001639 penicillamine Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 229960001031 glucose Drugs 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical group 0.000 description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 6
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- MNEMQJJMDDZXRO-REOHCLBHSA-N S‐phosphocysteine Chemical compound OC(=O)[C@@H](N)CSP(O)(O)=O MNEMQJJMDDZXRO-REOHCLBHSA-N 0.000 description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 239000000336 melanocortin receptor agonist Substances 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 3
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- WAMWSIDTKSNDCU-SSDOTTSWSA-N (2r)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@H](N)C1CCCCC1 WAMWSIDTKSNDCU-SSDOTTSWSA-N 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 description 2
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 2
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960000673 dextrose monohydrate Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229940124280 l-arginine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ORQXBVXKBGUSBA-MRVPVSSYSA-N (2r)-2-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)[C@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-MRVPVSSYSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 108700034262 4-Nle-7-Phe-alpha- MSH Proteins 0.000 description 1
- GDGFTEGUDDPSIT-UHFFFAOYSA-N 4-pyrimidin-4-ylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=NC=N1 GDGFTEGUDDPSIT-UHFFFAOYSA-N 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 1
- 101710115814 Adrenocorticotropic hormone receptor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008064 Corticotropin Receptors Human genes 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000754924 Homo sapiens Ribosomal oxygenase 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000001796 Melanocortin 4 receptors Human genes 0.000 description 1
- 108050009019 Melanocortin 4 receptors Proteins 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100022091 Ribosomal oxygenase 1 Human genes 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GHXXDFDIDHIEIL-WFBYXXMGSA-N Trp-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N GHXXDFDIDHIEIL-WFBYXXMGSA-N 0.000 description 1
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- UAHFGYDRQSXQEB-LEBBXHLNSA-N afamelanotide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-LEBBXHLNSA-N 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QDHYJVJAGQLHBA-UHFFFAOYSA-N beta-Ala-Gly Chemical compound NCCC(=O)NCC(O)=O QDHYJVJAGQLHBA-UHFFFAOYSA-N 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及黑皮质素受体(特别是黑皮质素4受体)的肽配体,其可用于治疗应答该受体的激活的病症,如胰岛素抵抗。
Description
发明背景
黑皮质素属于调节肽家族,其通过激素原阿黑皮素原(POMC;131个氨基酸长)的翻译后加工形成。POMC被加工成三类激素:黑皮质素、促肾上腺皮质激素,和多种内啡肽(例如,促脂解素)(Cone等人,Recent Prog.Horm.Res.,51:287-317,(1996);Cone等人,Ann.N.Y.Acad.Sci.,31:342-363,(1993))。
迄今已经表征了五种黑皮质素受体(MC-R)。这些包括黑素细胞特异性受体(MC1-R)、肾上腺皮质特异性ACTH受体(MC2-R)、黑皮质素-3(MC3-R)、黑皮质素-4(MC4-R)和黑皮质素-5受体(MC5-R)。所有的黑皮质素受体都应答肽激素类别的促黑激素(MSH)(Cone等人,Ann.N.Y.Acad.Sci.,680:342-363(1993);Cone等人,Recent Prog.Horm.Res.,51:287-318(1996))。
对黑皮质素受体(MC-R)作为设计用于治疗体重紊乱如肥胖和恶病质的新型治疗剂的靶标存在极大的兴趣。其中一个受体,MC4-R,是332个氨基酸的跨膜蛋白,其在脑以及胎盘和肠组织中表达(Cone等人,Ann.N.Y.Acad.Sci.,680:342-363(1993);Cone等人,Recent Prog.Horm.Res.,51:287-318(1996))。最近的药理学证明已经确定重要的MC4-R受体是分别为黑皮质素激动剂和拮抗剂报道的减食欲和促进食欲作用的主要介体(Giraudo等人,Brain Res.,809:302-306(1998);Farooqi等人,NE J Med.,348:1085-1095(2003);MacNeil等人,Eu.J.Pharm.,44:141-157(2002);MacNeil等人,Eu.J.Pharm.,450:93-109(2002);Kask等人,Neuroreport,10:707-711(1999);Chen等人,.Transgenic Res.,9:145-54,(2000);Marsh等人,Nat Genet.,21:119-22,(1999);Balthasar等人,Cell,123:493-505(2005))。
体重紊乱的并发症一般包括不能产生和利用胰岛素,其常常导致不完善的葡萄糖调节。不能适当控制葡萄糖代谢的结果影响整体健康的许多方面,包括能量代谢、神经病和心脏病。当前受体选择性黑皮质素受体配体的进展证明黑皮质素受体(尤其是MC4-R)活化作用在治疗葡萄糖调节(包括胰岛素代谢)中的治疗潜力。
发明概述
本发明涉及肽或其可药用盐治疗罹患胰岛素抵抗的哺乳动物的应用,所述肽是一种或更多种黑皮质素受体(MC-R)的配体。在一个实施方案中,所述配体是黑皮质素4受体的激动剂。在一个优选的实施方案中,所述黑皮质素受体配体是根据本文中描述的通式的配体或选自本文中描述的特定的肽。
胰岛素抵抗受试者哺乳动物可能肥胖或超重,其可能由于服用本发明的肽而体重减轻。胰岛素抵抗受试者哺乳动物也可能是正常体重或偏瘦。受试者哺乳动物的胰岛素抵抗状态可不依赖于体重减轻而进行治疗。此外,受试者哺乳动物可以是任何年龄的人类受试者,如婴儿、儿童、成人或老人。
在第一实施方案中,本发明提供治疗哺乳动物受试者的胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据通式(I)的黑皮质素受体4配体及其可药用盐、水合物、溶剂化物或前药(见公开号为WO2007/008704国际专利申请,此处整体引用作为参考):
(R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1
(I)
其中:
A1是Acc、HN-(CH2)m-C(O)、L-或D-氨基酸或缺失;
A2是Cys、D-Cys、hCys、D-hCys、Pen、D-Pen、Asp或Glu;
A3是Gly、Ala、β-Ala、Gaba、Aib、D-氨基酸或缺失;
A4是His、2-Pal、3-Pal、4-Pal、Taz、2-Thi、3-Thi或(X1,X2,X3,X4,X5)Phe;
A5是D-Phe、D-1-Nal、D-2-Nal、D-Trp、D-Bal、D-(X1,X2,X3,X4,X5)Phe、L-Phe或D-(Et)Tyr;
A6是Arg、hArg、Dab、Dap、Lys、Orn 或HN-CH((CH2)n-N(R4R5))-C(O);
A7是Trp、1-Nal、2-Nal、Bal、Bip、D-Trp、D-1-Nal、D-2-Nal、D-Bal或D-Bip;
A8是Gly、D-Ala、Acc、Ala、β-Ala、Gaba、Apn、Ahx、Aha、HN-(CH2)s-C(O)或缺失;
A9是Cys、D-Cys、hCys、D-hCys、Pen、D-Pen、Dab、Dap、Orn或Lys;
A10是Acc、HN-(CH2)t-C(O)、L-或D-氨基酸或缺失;
R1是-OH或-NH2;
R2和R3各自在每种情况下独立地选自H、(C1-C30)烷基、(C1-C30)杂烷基、(C1-C30)酰基、(C2-C30)烯基、(C2-C30)炔基、芳基(C1-C30)烷基、芳基(C1-C30)酰基、被取代的(C1-C30)烷基、被取代的(C1-C30)杂烷基、被取代的(C1-C30)酰基、被取代的(C2-C30)烯基、被取代的(C2-C30)炔基、被取代的芳基(C1-C30)烷基、和被取代的芳基(C1-C30)酰基;
R4和R5各自在每种情况下独立地是H、(C1-C40)烷基、(C1-C40)杂烷基、(C1-C40)酰基、(C2-C40)烯基、(C2-C40)炔基、芳基(C1-C40)烷基、芳基(C1-C40)酰基、被取代的(C1-C40)烷基、被取代的(C1-C40)杂烷基、被取代的(C1-C40)酰基、被取代的(C2-C40)烯基、被取代的(C2-C40)炔基、被取代的芳基(C1-C40)烷基、被取代的芳基(C1-C40)酰基、(C1-C40)烷基磺酰基或-C(NH)-NH2;
m在每种情况下独立地是1、2、3、4、5、6或7;
n在每种情况下独立地是1、2、3、4或5;
s在每种情况下独立地是1、2、3、4、5、6或7;
t在每种情况下独立地是1、2、3、4、5、6或7;
X1、X2、X3、X4和X5各自在每种情况下独立地是H、F、Cl、Br、I、(C1-10)烷基、被取代的(C1-10)烷基、(C2-10)烯基、被取代的(C2-10)烯基、(C2-10)炔基、被取代的(C2-10)炔基、芳基、被取代的芳基、OH、NH2、NO2或CN;
条件是
(I).当R4是(C1-C40)酰基、芳基(C1-C40)酰基、被取代的(C1-C40)酰基、被取代的芳基(C1-C40)酰基、(C1-C40)烷基磺酰基或-C(NH)-NH2时,那么R5是H或(C1-C40)烷基、(C1-C40)杂烷基、(C2-C40)烯基、(C2-C40)炔基、芳基(C1-C40)烷基、被取代的(C1-C40)烷基、被取代的(C1-C40)杂烷基、被取代的(C2-C40)烯基、被取代的(C2-C40)炔基或被取代的芳基(C1-C40)烷基;
(II).当R2为(C1-C30)酰基、芳基(C1-C30)酰基、被取代的(C1-C30)酰基、或被取代的芳基(C1-C30)酰基时,则R3是H、(C1-C30)烷基、(C1-C30)杂烷基、(C2-C30)烯基、(C2-C30)炔基、芳基(C1-C30)烷基、被取代的(C1-C30)烷基、被取代的(C1-C30)杂烷基、被取代的(C2-C30)烯基、被取代的(C2-C30)炔基、或被取代的芳基(C1-C30)烷基;
(III).A3或A8或两者必须存在于所述化合物中;
(IV).当A2是Cys、D-Cys、hCys、D-hCys、Pen或D-Pen时,则A9是Cys、D-Cys、hCys、D-hCys、Pen、或D-Pen;
(V).当A2是Asp或Glu时,则A9是Dab、Dap、Orn或Lys;
(VI).当A8是Ala或Gly时,则A1不是Nle;
(VII).当A1缺失时,则R2和R3不能都是H;
或其可药用盐。
在第一实施方案中的一个方面,本发明提供治疗哺乳动物受试者的胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的前面通式I之黑皮质素受体配体的亚组,其中:
A1是A6c、Arg、D-Arg、Cha、D-Cha、hCha、Chg、D-Chg、Gaba、Ile、Leu、hLeu、Met、β-hMet、2-Nal、D-2-Nal、Nip、Nle、Oic、Phe、D-Phe、hPhe、hPro、Val或缺失;
A2是Asp、Cys、D-Cys、hCys、D-hCys、Glu、Pen或D-Pen;
A3是D-Abu、Aib、Ala、β-Ala、D-Ala、D-Cha、Gaba、D-Glu、Gly、D-Ile、D-Leu、D-Tle、D-Val或缺失;
A4是His或3-Pal;
A5是D-Bal、D-1-Nal、D-2-Nal、D-Phe、D-Trp或D-(Et)Tyr;
A6是Arg或hArg;
A7是Bal、Bip、1-Nal、2-Nal、Trp、D-Trp;
A8是A6c、D-Ala、Aha、Ahx、Ala、β-Ala、Apn、Gaba、Gly或缺失;
A9是Cys、D-Cys、hCys、D-hCys、Lys、Pen或D-Pen;
A10是Thr或缺失;
其中A3或A8的至少一个但不是两者被缺失,
或其可药用盐。
根据通式(I)的配体的前面组更优选的化合物(其用于治疗哺乳动物受试者的胰岛素抵抗,伴随或不伴随体重减轻)是下述式的化合物:
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2;SEQ ID NO:1
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2;SEQ ID NO:1
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:2
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2;SEQ ID NO:3
D-Ph e-c(Cys-His-D-Ph e-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;SEQ ID NO:3
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:2
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;SEQ ID NO:4
Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:5
Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Phe-c(Asp-His-D-Ph e-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
正丁酰基-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:12
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2;SEQ ID NO:16
正丁酰基-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;SEQ IDNO:17
正丁酰基-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:17
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:61
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;SEQ ID NO:19
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;SEQ ID NO:20
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:21
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:23
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:24
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:25
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:24
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:26
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:27
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;SEQ ID NO:29
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:31
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;SEQ ID NO:36
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;SEQ ID NO:37
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:39
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:39
Ac-hPh e-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-β-Ala-Lys)-OH;SEQ ID NO:41
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;SEQ ID NO:42
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;SEQ ID NO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH;SEQ ID NO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;SEQ ID NO:43
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;SEQ ID NO:42
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;SEQ ID NO:41
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;SEQ ID NO:29
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;SEQ ID NO:47
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;SEQ ID NO:29
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH;SEQ ID NO:48
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:49
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:51
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:52
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:52
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:51
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:53
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:53
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:24
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:27
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2;SEQ ID NO:1
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:2
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;SEQ ID NO:3
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:2
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;SEQ ID NO:4
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:21
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:23
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:25
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:24
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:26
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;SEQ ID NO:29
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:31
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;SEQ ID NO:36
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;SEQ ID NO:37
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;SEQ ID NO:20
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:39
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:39
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40或
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:49
或其可药用盐。
在第二实施方案中,本发明提供治疗哺乳动物受试者中胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据通式(II)的黑皮质素受体配体及其可药用盐、水合物、溶剂化物或前药(见公开号为WO2007/008704国际专利申请,此处整体引用作为参考):
(R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-NH2
(II)
其中:
A1是Nle或缺失;
A2是Cys或Asp;
A3是Glu或D-Ala;
A4是His;
A5是D-Phe;
A6是Arg;
A7是Trp、2-Nal或Bal;
A8是Gly、Ala、D-Ala、β-Ala、Gaba或Apn;
A9是Cys或Lys;
R2和R3各自独立地选自H或(C1-C6)酰基;
条件是
(I).当R2是(C1-C6)酰基时,则R3是H;
(II).当A2是Cys时,则A9是Cys,
或其可药用盐。
前面组的化合物更优选的(其用于治疗哺乳动物受试者中胰岛素抵抗,伴随或不伴随体重减轻)是下述式的化合物:
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:54
Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:55
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;SEQ ID NO:55
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:56
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;SEQ ID NO:56
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;SEQ ID NO:57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:57或
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2;SEQ ID NO:58
或其可药用盐。
在第三实施方案中,本发明提供治疗哺乳动物受试者的胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据式(III)的黑皮质素受体化合物、及其可药用盐、水合物、溶剂化物或前药(见公开号为WO2007/008684国际专利申请,此处整体引用作为参考):
(R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1
(III)
其中:
B1是含有5、6、7、8、9、10、11、12、13、14或15个氨基酸的肽部分,其中至少5个氨基酸独立地选自L-Arg、D-Arg、L-hArg和D-hArg,或B1任选缺失;
A1是Acc、HN-(CH2)m-C(O)、L-或D-氨基酸或缺失;
A2是Cys、D-Cys、hCys、D-hCys、Pen、D-Pen、Asp或Glu;
A3是Gly、Glu、Ala、β-Ala、Gaba、Aib、D-氨基酸或缺失;
A4是His、2-Pal、3-Pal、4-Pal、Taz、2-Thi、3-Thi或(X1,X2,X3,X4,X5)Phe;
A5是D-Phe、D-1-Nal、D-2-Nal、D-Trp、D-Bal、D-(X1,X2,X3,X4,X5)Phe、D-(Et)Tyr、D-Dip、D-Bip或D-Bpa;
A6是Arg、hArg、Dab、Dap、Lys、Orn或HN-CH((CH2)n-N(R4R5))-C(O);
A7是Trp、1-Nal、2-Nal、Bal、Bip、Dip、Bpa、D-Trp、D-1-Nal、D-2-Nal、D-Bal、D-Bip、D-Dip或D-Bpa;
A8是Gly、D-Ala、Ace、Ala、β-Ala、Gaba、Apn、Ahx、Aha、HN-(CH2)s-C(O)或缺失;
A9是Cys、D-Cys、hCys、D-hCys、Pen、D-Pen、Dab、Dap、Orn或Lys;
A10是Acc、HN-(CH2)t-C(O)、Pro、hPro、3-Hyp、4-Hyp、Thr、L-或D-氨基酸或缺失;
A11是Pro、hPro、3-Hyp、4-Hyp或缺失;
A12是Lys、Dab、Dap、Arg、hArg或缺失;
A13是Asp、Glu或缺失;
B2是含有1、2、3、4或5个氨基酸的肽部分或缺失,
B3是含有5、6、7、8、9、10、11、12、13、14或15个氨基酸的肽部分,其中至少5个氨基酸独立地选自L-Arg、D-Arg、L-hArg和D-hArg或缺失;
R1是-OH或-NH2;
R2和R3各自在每种情况下独立地选自H、(C1-C30)烷基、(C1-C30)杂烷基、(C1-C30)酰基、(C2-C30)烯基、(C2-C30)炔基、芳基(C1-C30)烷基、芳基(C1-C30)酰基、被取代的(C1-C30)烷基、被取代的(C1-C30)杂烷基、被取代的(C1-C30)酰基、被取代的(C2-C30)烯基、被取代的(C2-C30)炔基、被取代的芳基(C1-C30)烷基、和被取代的芳基(C1-C30)酰基;
R4和R5各自在每种情况下独立地是H、(C1-C40)烷基、(C1-C40)杂烷基、(C1-C40)酰基、(C2-C40)烯基、(C2-C40)炔基、芳基(C1-C40)烷基、芳基(C1-C40)酰基、被取代的(C1-C40)烷基、被取代的(C1-C40)杂烷基、被取代的(C1-C40)酰基、被取代的(C2-C40)烯基、被取代的(C2-C40)炔基、被取代的芳基(C1-C40)烷基、被取代的芳基(C1-C40)酰基、(C1-C40)烷基磺酰基或-C(NH)-NH2;
n在每种情况下独立地是1、2、3、4或5;
m在每种情况下独立地是1、2、3、4、5、6或7;
s在每种情况下独立地是1、2、3、4、5、6或7;
t在每种情况下独立地是1、2、3、4、5、6或7;
X1、X2、X3、X4和X5各自在每种情况下独立地是H、F、Cl、Br、I、(C1-10)烷基、被取代的(C1-10)烷基、(C2-10)烯基、被取代的(C2-10)烯基、(C2-10)炔基、被取代的(C2-10)炔基、芳基、被取代的芳基、OH、NH2、NO2或CN;
条件是
(I).当R4是(C1-C40)酰基、芳基(C1-C40)酰基、被取代的(C1-C40)酰基、被取代的芳基(C1-C40)酰基、(C1-C40)烷基磺酰基或-C(NH)-NH2时,则R5是H、(C1-C40)烷基、(C1-C40)杂烷基、(C2-C40)烯基、(C2-C40)炔基、芳基(C1-C40)烷基、被取代的(C1-C40)烷基、被取代的(C1-C40)杂烷基、被取代的(C2-C40)烯基、被取代的(C2-C40)炔基或被取代的芳基(C1-C40)烷基;
(II).当R2为(C1-C30)酰基、芳基(C1-C30)酰基、被取代的(C1-C30)酰基、或被取代的芳基(C1-C30)酰基时,则R3是H、(C1-C30)烷基、(C1-C30)杂烷基、(C2-C30)烯基、(C2-C30)炔基、芳基(C1-C30)烷基、被取代的(C1-C30)烷基、被取代的(C1-C30)杂烷基、被取代的(C2-C30)烯基、被取代的(C2-C30)炔基、或被取代的芳基(C1-C30)烷基;
(III)B1和B2都不含有一种或更多种下述氨基酸序列:
Arg-(Lys)2-(Arg)2-Gln-(Arg)3、
Tyr-Ala-Arg-Lys-Ala-(Arg)2-Gln-Ala-(Arg)2、
Tyr-Ala-Arg-(Ala)2-(Arg)2-(Ala)2-(Arg)2、Tyr-Ala-(Arg)9、
Tyr-(Ala)3-(Arg)7、Tyr-Ala-Arg-Ala-Pro-(Arg)2-Ala-(Arg)3或
Tyr-Ala-Arg-Ala-Pro-(Arg)2-Pro-(Arg)2;
(IV)B1或B2之一或两者必须存在于所述化合物中;
(V)当A2是Cys、D-Cys、hCys、D-hCys、Pen或D-Pen时,则A9是Cys、D-Cys、hCys、D-hCys、Pen或D-Pen;
(VI)当A2是Asp或Glu时,则A9是Dab、Dap、Orn或Lys;
或其可药用盐。
在第三实施方案中的一个方面,本发明涉及通式(III)的化合物治疗哺乳动物受试者中胰岛素抵抗的应用(伴随或不伴随体重减轻),其中
B1是Arg-Lys-Gln-Lys-(Arg)5、Arg-(Lys)2-Arg-Gln-(Arg)4、Arg-(Lys)2-(Arg)3-Gln-(Arg)2、Arg-(Lys)2-(Arg)4-Gln-Arg 、Arg-(Lys)2-(Arg)5-Gln、Arg-(Lys)2-Gln-(Arg)5、Arg-Gln-(Lys)2-(Arg)5、Arg-Gln-(Arg)7、Arg-Gln-(Arg)8、(Arg)2-Gln-(Arg)6、(Arg)2-Gln-(Arg)7、(Arg)3-Gln-(Arg)5、(Arg)3-Gln-(Arg)6、(Arg)4-Gln-(Arg)4、(Arg)4-Gln-(Arg)5、(Arg)5、(Arg)5-Gln-(Arg)3、(Arg)5-Gln-(Arg)4、(Arg)6、(Arg)6-Gln-(Arg)3、(Arg)7、(Arg)7-Gln-(Arg)2、(Arg)8、(Arg)8-Gln-Arg、(Arg)9、(Arg)9-Gln、(D-Arg)5、(D-Arg)6、(D-Arg)7、(D-Arg)8、(D-Arg)9、Gln-Arg-(Lys)2-(Arg)5、Gln-(Arg)8、Gln-(Arg)9、Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3、Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Doc;或缺失;
B2是β-Ala、β-Ala-Gly、β-Ala-Tyr、β-Ala-Tyr-Gly、(β-Ala)2、(β-Ala)2-Gly、(β-Ala)2-Tyr、(β-Ala)2-Tyr-Gly、Doc、Doc-Gly、Doc-Tyr、Doc-Tyr-Gly、(Doc)2、(Doc)2-Gly、(Doc)2-Tyr、Doc)2-Tyr-Gly或缺失;
B3是Arg-Lys-Gln-Lys-(Arg)5、Arg-Lys-(Arg)3-Gln-(Arg)3、Arg-(Lys)2-Arg-Gln-(Arg)4、Arg-(Lys)2-Gln-(Arg)5、Arg-(Lys)2-(Arg)2-Gln-(Arg)3、Arg-(Lys)2-(Arg)3-Gln-(Arg)2、Arg-(Lys)2-(Arg)4-Gln-Arg、Arg-(Lys)2-(Arg)5-Gln、Arg-Gln-(Lys)2-(Arg)5、Arg-Gln-(Arg)7、Arg-Gln-(Arg)8、(Arg)2-Lys-(Arg)2-Gln-(Arg)3、(Arg)2-Gln-(Arg)6、(Arg)2-Gln-(Arg)7、(Arg)3-Gln-(Arg)5、(Arg)3-Gln-(Arg)6、(Arg)4-Gln-(Arg)4、(Arg)4-Gln-(Arg)5、(Arg)5、(Arg)5-Gln-(Arg)3、(Arg)5-Gln-(Arg)4、(Arg)6、(Arg)6-Gln-(Arg)3、(Arg)7、(Arg)7-Gln-(Arg)2、(Arg)8、(Arg)8-Gln-Arg、(Arg)9、(Arg)9-Gln、(D-Arg)5、(D-Arg)6、(D-Arg)7、(D-Arg)8、(D-Arg)9、Gln-Arg-(Lys)2-(Arg)5、Gln-(Arg)8、Gln-(Arg)9或缺失;
A1是A6c、Cha、hCha、Chg、D-Chg、hChg、Gaba、hLeu、Met、β-hMet、D-2-Nal、Nip、Nle、Oic、Phe、D-Phe、hPhe、hPro或缺失;
A2是Cys
A3是D-Abu、Aib、Ala、β-Ala、D-Ala、D-Cha、Gaba、Glu、Gly、D-Ile、D-Leu、D-Met、D-Nle、D-Phe、D-Tle、D-Trp、D-Tyr、D-Val或缺失;
A4是His;
A5是D-Bal、D-1-Nal、D-2-Nal、D-Phe、D-(X1,X2,X3,X4,X5)Phe、D-Trp或D-(Et)Tyr;
A6是Arg或hArg;
A7是Bal、Bip、1-Nal、2-Nal、Trp或D-Trp;
A8是A5c、A6c、Aha、Ahx、Ala、β-Ala、Apn、Gaba、Gly或缺失;
A9是Cys、D-Cys、hCys、D-hCys、Lys、Pen或D-Pen;
A10是Pro、Thr或缺失;
A11是Pro或缺失;
A12是arg、Lys或缺失;
A13是Asp或缺失;
R2和R3各自独立地是H或酰基;
或其可药用盐。
根据通式(III)化合物前面组的优选的配体(其用于治疗哺乳动物受试者之胰岛素抵抗,伴随或不伴随体重减轻)是下述式的化合物:
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;(SEQ ID NO:60)
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;(SEQ ID NO:61)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:62)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:62)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:63)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:64)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:65)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:66)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:67)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:68)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:69)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:70)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:72)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:73)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:74)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:75)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Gln-(Arg)5-NH2;(SEQ ID NO:76)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-(Arg)5-NH2;(SEQ ID NO:77)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)4-Gln-Arg-NH2;(SEQ ID NO:78)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Aib-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:79)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:84)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)3-Gln-(Arg)2-NH2;(SEQ ID NO:85)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Gln-(Lys)2-(Arg)5-NH2;(SEQ ID NO:86)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)5-Gln-NH2;(SEQ ID NO:87)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:89)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:90)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:91)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:93)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:94)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:95)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:96)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:97)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:98)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:99)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:103)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:104)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:105)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:103)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:106)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Gln-(Arg)5-NH2;(SEQ ID NO:107)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-(Arg)5-NH2;(SEQ ID NO:108)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Gln-(Lys)2-(Arg)5-NH2;(SEQ ID NO:109)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)3-Gln-(Arg)2-NH2;(SEQ ID NO:110)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)4-Gln-Arg-NH2;(SEQ ID NO:111)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)5-Gln-NH2;(SEQ ID NO:112)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SE Q ID NO:116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:117)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:117)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:119)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:119)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:123)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:123)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:124)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:124)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:129)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:129)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:131)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:131)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:132)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:133)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:133)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:135)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:135)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:137)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:139)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:140)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:141)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:142)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:143)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:144)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:145)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:146)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:147)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:147)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:148)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:158)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:159)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:160)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:161)
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:162)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:175)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:176)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:177)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:178)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:179)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:180)
Ac-Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:181)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:182)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:183)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:184)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:183)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:185)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:186)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:185)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:186)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:187)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:192)
Ac-bCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:194)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:195)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:196)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:197)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:198)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Ph e-Arg-D-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Ph e-Arg-D-Trp-β-Ala-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:201)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:202)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:208)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:210)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:211)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:212)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-la)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:267)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:214)
D-Ph e-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:216)
D-Ph e-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:217)
D-Ph e-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:220)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Th r-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:226)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:229)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:230)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:232)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:231)
D-Ph e-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:232)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:233)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:234)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:237)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:238)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:237)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:238)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:239)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:242)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:250)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:258)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:265)或
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:266);
或其可药用盐。
在第四实施方案中,本发明提供治疗哺乳动物受试者中胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据通式(IV)的黑皮质素受体化合物,及其可药用盐、水合物、溶剂化物或前药,使用具有下述通式的化合物(通式(IV)):
Ac-c(Cys-Glu-His-A1-Arg-A2-A3-Cys)-(Pro)2-Lys-Asp-NH2
(IV)
其中:
A1是X-Phe或2-Nal的D-异构体,其中X是卤素;
A2是Bal、1-Nal、2-Nal或Trp;
A3是Aib、Ala、β-Ala或Gly,
或其可药用盐。
发现用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的前面通式的优选的化合物包括下述化合物:
Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:268)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:2690)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-β-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:270)或
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:270)
或其可药用盐。
本发明另外提供治疗哺乳动物受试者中胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据通式(V)、(VI)或(VII)的通过乙内酰脲部分修饰的黑皮质素受体化合物,及其可药用盐、水合物、溶剂化物或前药。
根据第五实施方案,本发明提供治疗哺乳动物受试者中胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据下述通式(通式(V))的黑皮质素受体配体,其可药用盐、水合物、溶剂化物和/或前药(见申请号为PCT/US08/06675国际专利申请,此处整体引用作为参考):
其中
X选自-CH2-S-S-CH2-、-C(CH3)2-S-S-CH2-、-CH2-S-S-C(CH3)2-、-C(CH3)2-S-S-C(CH3)2-、-(CH2)2-S-S-CH2-、-CH2-S-S-(CH2)2-、-(CH2)2-S-S-(CH2)2-、-C(CH3)2-S-S-(CH2)2-、-(CH2)2-S-S-C(CH3)2-、-(CH2)t-C(O)-NR8-(CH2)r-和-(CH2)r-NR8-C(O)-(CH2)t-;
R1和R2各自独立地是H、(C1-C10)烷基或被取代的(C1-C10)烷基;
R3是-OH或-NH2;
R4和R5各自独立地是H、(C1-C10)烷基或被取代的(C1-C10)烷基;
A1是His、2-Pal、3-Pal、4-Pal、(X1,X2,X3,X4,X5)Phe、Taz、2-Thi、3-Thi或缺失;
A2是D-Bal、D-1-Nal、D-2-Nal、D-Phe或D-(X1,X2,X3,X4X5)Phe;
A3是Arg、hArg、Dab、Dap、Lys或Orn;
A4是Bal、1-Nal、2-Nal、(X1,X2,X3,X4,X5)Phe或Trp;
R6和R7各自在其每种情况下独立地是H、(C1-C10)烷基、(C1-C10)杂烷基、芳基(C1-C5)烷基、被取代的(C1-C10)烷基、被取代的(C1-C10)杂烷基或被取代的芳基(C1-C5)烷基,条件是R6和R7可以结合在一起形成环;
R8是H、(C1-C10)烷基或被取代的(C1-C10)烷基;
r在其每种情况下独立地是1、2、3、4或5;
t在其每种情况下独立地是1或2。
优选地,发现用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的根据前面通式的化合物包括化合物其中X1选自:
用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的前面种类的化合物的代表性实施方案如下:
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:271)
c[乙内酰脲(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:271)
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;(SEQID NO:272)或
c[乙内酰脲(C(O)-(h Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;(SEQ ID NO:272)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2;(SEQID NO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;(SEQID NO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;(SEQID NO:273)或
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;(SEQID NO:273)
c[乙内酰脲(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH2(SEQ ID NO:274)
c[乙内酰脲(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-A5c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-A6c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-Aic))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-Apc))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ IDNO:275)
c[乙内酰脲-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;(SEQID NO:276)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;(SEQID NO:276)或
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2,(SEQID NO:276)
c[乙内酰脲(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH2(SEQ IDNO:277)
根据第六实施方案,本发明提供治疗哺乳动物受试者中胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据通式(VI)的黑皮质素受体化合物,其可药用盐、水合物、溶剂化物和/或前药(见申请号为PCT/US08/06675国际专利申请,此处整体引用作为参考):
其中
A1是Asp、Cys、D-Cys、Dab、Dap、Glu、Lys、Orn,Pen或D-Pen;
A2是L-或D-氨基酸;
A3是His、2-Pal、3-Pal、4-Pal、(X1,X2,X3,X4,X5)Phe、Taz、2-Thi或3-Thi;
A4是D-Bal、D-1-Nal、D-2-Nal、D-Phe或D-(X1,X2,X3,X4,X5)Phe;
A5是Arg、hArg、Dab、Dap、Lys或Orn;
A6是Bal、1-Nal、2-Nal、(X1,X2,X3,X4,X5)Phe或Trp、;
A7是Asp、Cys、D-Cys、Dab、Dap、Glu、Lys、Orn、Pen或D-Pen;
R1是H、(C1-C10)烷基或被取代的(C1-C10)烷基;
R2和R3各自独立地是H、(C1-C10)烷基、(C1-C10)杂烷基、芳基(C1-C5)烷基、被取代的(C1-C10)烷基、被取代的(C1-C10)杂烷基或被取代的芳基(C1-C5)烷基或R2和R3可融合在一起形成环部分;
R4是CO2H或C(O)NH2;
R5和R6各自独立地是H、(C1-C10)烷基、(C1-C10)杂烷基、芳基(C1-C5)烷基、被取代的(C1-C10)烷基、被取代的(C1-C10)杂烷基或被取代的芳基(C1-C5)烷基或R5和R6可融合在一起形成环部分;
R7和R8各自独立地是H、(C1-C10)烷基、(C1-C10)杂烷基、芳基(C1-C5)烷基、被取代的(C1-C10)烷基、被取代的(C1-C10)杂烷基或被取代的芳基(C1-C5)烷基;或R7和R8可融合在一起形成环部分;
R9是H、(C1-C10)烷基或被取代的(C1-C10)烷基;
n在其每种情况下独立地是1、2、3、4、5、6或7;
或其可药用盐。
用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的根据通式(VI)的优选种类的化合物是那些化合物其中:
A1是Cys;
A2是D-Ala、Asn、Asp、Gln、Glu或D-Phe;
A3是His;
A4是D-2-Nal或D-Phe;
A5是Arg;
A6是Trp;
A7是Cys或Pen;
R1、R2、R3和R9各自独立地是H;
R4是C(O)NH2;
R5和R6各自独立地是H、(C1-C10)烷基、(C1-C10)杂烷基、被取代的(C1-C10)烷基或被取代的(C1-C10)杂烷基或R5和R6可融合在一起形成环部分;
R7和R8各自独立地是H、(C1-C10)烷基、(C1-C10)杂烷基、被取代的(C1-C10)烷基或被取代的(C1-C10)杂烷基;
或其可药用盐。
用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的根据前面通式(通式(VI))的优选的化合物包括:
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:281)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:281)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:282)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:282)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Ph e-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)或
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
乙内酰脲(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
乙内酰脲(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
乙内酰脲(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)或
乙内酰脲(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:285)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:285)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:286)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:286)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:287)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:287)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:288)和
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:288)
乙内酰脲(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:289);
或其可药用盐。
在第七实施方案中,本发明提供治疗哺乳动物受试者中胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的属于环肽类似物种类的黑皮质素受体配体,该环肽类似物是具有如下描述的根据通式(VII)的结构的黑皮质素受体配体(见申请号为PCT/US08/06675国际专利申请,此处整体引用作为参考):
其中
X选自-CH2-S-S-CH2-、-C(CH3)2-S-S-CH2-、-CH2-S-S-C(CH3)2-、-C(CH3)2-S-S-C(CH3)2-、-(CH2)2-S-S-CH2-、-CH2-S-S-(CH2)2、-(CH2)2-S-S-(CH2)2-、-C(CH3)2-S-S-(CH2)2-、-(CH2)2-S-S-C(CH3)2-、-(CH2)t-C(O)-NR8-(CH2)r-和-(CH2)r-NR8-C(O)-(CH2)t-;
R1和R5各自独立地是H、(C1-C10)烷基或被取代的(C1-C10)烷基;
R2和R3各自独立地是H、(C1-C10)烷基、(C1-C10)杂烷基、芳基(C1-C5)烷基、被取代的(C1-C10)烷基、被取代的(C1-C10)杂烷基或被取代的芳基(C1-C5)烷基或R2和R3可融合在一起形成环;
R4是OH或NH2;
R6和R7各自独立地是H、(C1-C10)烷基或被取代的(C1-C10)烷基;
A1是L-或D-氨基酸或缺失;
A2是His、2-Pal、3-Pal、4-Pal、(X1,X2,X3,X4,X5)Phe、Taz、2-Thi或3-Thi;
A3是D-Bal、D-1-Nal、D-2-Nal、D-Phe或D-(X1,X2,X3,X4,X5)Phe;
A4是Arg、hArg、Dab、Dap、Lys或Orn,;
A5是Bal、1-Nal、2-Nal、(X1,X2,X3,X4,X5)Phe或Trp,;
r在其每种情况下独立地是1、2、3、4或5;
t在其每种情况下独立地是1或2;
或其可药用盐。
用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的根据通式(VII)的化合物的优选方面中,
A1是Ala、D-Ala、Asn、Asp、Gln、Glu或Gly;
或其可药用盐。
用于治疗哺乳动物受试者中胰岛素抵抗的根据通式(VII)的优选化合物包括下述化合物:
c[乙内酰脲(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)或
c[乙内酰脲(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:291)或
c[乙内酰脲(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2(SEQID NO:291);
或其可药用盐。
在第八实施方案中,本发明涉及治疗哺乳动物受试者中胰岛素抵抗的方法(伴随或不伴随体重减轻),通过施用治疗有效量的根据通式(VIII)的黑皮质素受体配体(见申请号为PCT/US08/07411国际专利申请,此处整体引用作为参考):
(R2R3)-A0-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1
(VIII)
其中:
A0是芳香族的氨基酸
A1是Acc、HN-(CH2)m-C(O)、L-或D-氨基酸;
A2是Asp、Cys、D-Cys、hCys、D-hCys、Glu、Pen或D-Pen;
A3是Aib、Ala、β-Ala、Gaba、Gly或D-氨基酸;
A4是His、2-Pal、3-Pal、4-Pal、(X1,X2,X3,X4,X5)Phe、Taz、2-Thi或3-Thi;
A5是D-Bal、D-1-Nal、D-2-Nal、D-Phe、L-Phe、D-(X1,X2X3X4X5)Phe、L-Ph e、D-Trp或D-(Et)Tyr;
A6是Arg、hArg、Dab、Dap、Lys、Orn或HN-CH((CH2)n-N(R4R5))-C(O);
A7是Bal、D-Bal、Bip、D-Bip、1-Nal、D-1-Nal、2-Nal、D-2-Nal或D-Trp;
A8是Acc、Aha、Ahx、Ala、D-Ala、β-Ala、Apn、Gaba、Gly、HN-(CH2)s-C(O)或缺失;
A9是Cys、D-Cys、hCys、D-hCys、Dab、Dap、Lys、Orn、Pen或D-Pen;
A10是Acc、HN-(CH2)t-C(O)、L-或D-氨基酸或缺失;
R1是OH或NH2;
R2和R3各自在每种情况下独立地选自H、(C1-C30)烷基、(C1-C30)杂烷基、(C1-C30)酰基、(C2-C30)烯基、(C2-C30)炔基、芳基(C1-C30)烷基、芳基(C1-C30)酰基、被取代的(C1-C30)烷基、被取代的(C1-C30)杂烷基、被取代的(C1-C30)酰基、被取代的(C2-C30)烯基、被取代的(C2-C30)炔基、被取代的芳基(C1-C30)烷基和被取代的芳基(C1-C30)酰基;
R4和R5各自在每种情况下独立地是H、(C1-C40)烷基、(C1-C40)杂烷基、(C1-C40)酰基、(C2-C40)烯基、(C2-C40)炔基、芳基(C1-C40)烷基、芳基(C1-C40)酰基、被取代的(C1-C40)烷基、被取代的(C1-C40)杂烷基、被取代的(C1-C40)酰基、被取代的(C2-C40)烯基、被取代的(C2-C40)炔基、被取代的芳基(C1-C40)烷基、被取代的芳基(C1-C40)酰基、(C1-C40)烷基磺酰基或-C(NH)-NH2;
m在每种情况下独立地是1、2、3、4、5、6或7;
n在每种情况下独立地是1、2、3、4或5;
s在每种情况下独立地是1、2、3、4、5、6或7;
t在每种情况下独立地是1、2、3、4、5、6或7;
X1、X2、X3、X4和X5各自在每种情况下独立地是H、F、Cl、Br、I、(C1-10)烷基、被取代的(C1-10)烷基、(C2-10)烯基、被取代的(C2-10)烯基、(C2-10)炔基、被取代的(C2-10)炔基、芳基、被取代的芳基、OH、NH2、NO2或CN;
条件是
(I).当R4是(C1-C40)酰基、芳基(C1-C40)酰基、被取代的(C1-C40)酰基、被取代的芳基(C1-C40)酰基、(C1-C40)烷基磺酰基或-C(NH)-NH2时,那么R5是H或(C1-C40)烷基、(C1-C40)杂烷基、(C2-C40)烯基、(C2-C40)炔基、芳基(C1-C40)烷基、被取代的(C1-C40)烷基、被取代的(C1-C40)杂烷基、被取代的(C2-C40)烯基、被取代的(C2-C40)炔基或被取代的芳基(C1-C40)烷基;
(II).当R2是(C1-C30)酰基、芳基(C1-C30)酰基、被取代的(C1-C30)酰基或被取代的芳基(C1-C30)酰基时,那么R3是H、(C1-C30)烷基、(C1-C30)杂烷基、(C2-C30)烯基、(C2-C30)炔基、芳基(C1-C30)烷基、被取代的(C1-C30)烷基、被取代的(C1-C30)杂烷基、被取代的(C2-C30)烯基、被取代的(C2-C30)炔基或被取代的芳基(C1-C30)烷基;
(III).当A2是Cys、D-Cys、hCys、D-hCys、Pen或D-Pen时,那么A9是Cys、D-Cys、hCys、D-hCys、Pen或D-Pen;
(IV).当A2是Asp或Glu时,那么A9是Dab、Dap、Orn或Lys;
(V).当A8是Ala或Gly时,那么A1不是Nle;或
其可药用盐。
用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的前面通式的优选的一组化合物是其中
A0是1-Nal、2-Nal、His、Pff、Phe、Trp或Tyr;
A1是Arg;
A2是Cys;
A3是D-Ala;
A4是His;
A5是D-Phe;
A6是Arg;
A7是Trp;
A8缺失;
A9是Cys;
A10缺失;
或其可药用盐。
用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻)的前面组的化合物中优选的化合物具有下述通式:
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:293)或
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
或其可药用盐。
在又一个优选实施方案中,如上述所限定的通式(I)、(II)、(III)、(IV)、(V)、(VI)、(VII)或(VIII)的一种或多种化合物,其用于治疗哺乳动物受试者中胰岛素抵抗(伴随或不伴随体重减轻),或该化合物的可药用盐,以使用可药用载体或稀释剂的组合物形式提供给所述有需要的受试者。
在优选的实施方案中,本发明提供治疗有其需要的受试者之胰岛素抵抗的方法,包括外周施用有效量的黑皮质素受体4激动剂来治疗有其需要的受试者的胰岛素抵抗。
在一个方面,用于治疗有其需要的受试者的胰岛素抵抗(伴随或不伴随体重降低)的黑皮质素受体4激动剂选自:
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2;SEQ ID NO:1
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2;SEQ ID NO:1
Ac-Nle-c(Cys-His-D-Ph e-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:2
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2;SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;SEQ IDNO:3
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:2
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;SEQ ID NO:4
Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:5
Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ IDNO:10
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ IDNO:10
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ IDNO:10
Ac-Nle-c(D-Cys-Aib-His-D-Ph e-Arg-Trp-D-Cys)-NH2;SE Q ID NO:10
Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
正丁酰基-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ IDNO:12
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ IDNO:11
Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;SEQ IDNO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2;SEQ IDNO:16
正丁酰基-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;SEQ IDNO:17
正丁酰基-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ IDNO:17
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:61
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;SEQ ID NO:19
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;SEQ ID NO:20
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:21
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:23
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:24
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:25
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQID NO:24
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQID NO:26
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:27
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;SEQ ID NO:29
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:31
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;SEQ ID NO:36
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;SEQ ID NO:37
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:39
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:39
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH;SEQ ID NO:41
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;SEQ ID NO:42
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;SEQ IDNO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH;SEQ IDNO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;SEQ IDNO:43
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;SEQ ID NO:42
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;SEQ ID NO:41
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;SEQ ID NO:47
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH;SEQ ID NO:48
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:49
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:51
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:52
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:52
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:51
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:53
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:53
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2;SEQ IDNO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2;SEQ IDNO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;SEQ IDNO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ IDNO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ IDNO:54
Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:55
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;SEQ ID NO:55
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:56
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;SEQ ID NO:56
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ IDNO:57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;SEQ IDNO:57
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2;SEQ IDNO:58
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;(SE Q ID NO:60)
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;(SEQ ID NO:61)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:62)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:62)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:63)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:64)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:65)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO66)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:67)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:68)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:69)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:70)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:72)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:73)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:74)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:75)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Gln-(Arg)5-NH2;(SEQ ID NO:76)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-(Arg)5-NH2;(SEQ ID NO:77)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)4-Gln-Arg-NH2;(SEQ ID NO:78)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Aib-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:79)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:84)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)3-Gln-(Arg)2-NH2;(SEQ ID NO:85)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Gln-(Lys)2-(Arg)5-NH2;(SEQ ID NO:86)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)5-Gln-NH2;(SEQ ID NO:87)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(PrO)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:89)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:90)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:91)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:95)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:96)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SE Q ID NO:97)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:98)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:99)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:104)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:105)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:103)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:119)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:124)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:133)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:135)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:135)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:137)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:139)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:140)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:141)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SE Q ID NO:143)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:144)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:149);
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:158)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:159)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:160)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:161)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:162)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:175)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:176)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:177)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:178)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:179)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:180)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:181)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:182)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:183)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:184)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:183)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:185)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:186)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:185)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:186)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:187)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:194)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:195)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:196)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:197)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:198)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:201)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:202)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Pen)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Pen)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Pen)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:208)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:210)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:211)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:212)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:267)
D-Ph e-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:216)
D-Ph e-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:215)
D-Ph e-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:217)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:220)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:226)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:229)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:230)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:232)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:231)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:232)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:233)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:234)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:242)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:250)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:258)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:262)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:266)
Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:268)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-β-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:270)
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:271)
c[乙内酰脲(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:271)
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;(SEQID NO:272)
c[乙内酰脲(C(O)-(hCys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;(SEQ ID NO:272)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2;(SEQID NO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;(SEQID NO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;(SEQID NO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;(SEQID NO:273)
c[乙内酰脲(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-A5c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-A6c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-Aic))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-Apc))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:274)
c[乙内酰脲(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;(SEQID NO:276)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;(SEQID NO:276)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;(SEQID NO:276)
c[乙内酰脲(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH2;(SEQ IDNO:277)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:281)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:281)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:282)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:282)
乙内酰脲(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
乙内酰脲(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
乙内酰脲(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
乙内酰脲(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:285)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:285)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:286)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:286)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:287)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:288)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:288)
乙内酰脲(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:289)
c[乙内酰脲(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2、(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Leu-Cys))-D-Ala-His-D-Ph e-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:291)
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:293)和
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
或其可药用盐。
在一个优选的方面,用于治疗有其需要的受试者的胰岛素抵抗的黑皮质素受体4激动剂是Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:50)或其可药用盐。在另一个优选的方面,用于治疗有其需要的受试者的胰岛素抵抗的黑皮质素受体4激动剂是乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ IDNO:278)或其可药用盐。
在本发明的其他方面,对用于治疗胰岛素抵抗的本发明之化合物或包含化合物的组合物或化合物的可药用盐的施用是连续的、每小时的、每天四次、每天三次、每天两次、每天一次、每隔一天一次、每周两次、每周一次、每两周一次、每月一次、每两月一次、或更长。
需要治疗的受试者可以是肥胖的、超重的、正常体重的或偏瘦的。肥胖、超重、正常体重或偏瘦的受试者可罹患II型糖尿病。对用于治疗胰岛素抵抗的本发明之化合物或包含化合物的组合物或化合物的可药用盐的优选施用是外周施用。外周施用的例子包括通过经口、皮下、腹膜内、肌内、静脉内、直肠、经皮、或鼻内形式的施用。
附图简述
图1:施用100nmole/Kg所选化合物后6小时,在禁食大鼠中消耗的食物。
图2.皮下施用75、300或600nmole/kg/天的化合物A对大鼠(A)体重、(B)累积食物摄取、(C)胰岛素水平和(D)葡萄糖水平的影响。
图3.皮下施用75、300或600nmole/kg/天的化合物B对大鼠(A)体重、(B)累积食物摄取、(C)胰岛素水平和(D)葡萄糖水平的影响。
图4.皮下施用200、600或1800nmole/kg/天的化合物A对小鼠血糖水平的影响。
图5.腹膜内施用6.4μmole/kg的化合物A对肥胖小鼠血糖水平的影响。
发明详述
最近的研究报道全世界超重的人的数目惊人,他们受到很多种严重和花费巨大的健康问题的困扰。根据世界卫生组织报道(Kouris-Blazos等人在Asia Pac.J.Clin.Nutr.,2007,16:329-338中所报道),估计全世界有10亿人超重,他们之中估计有3亿人肥胖。估计有2千2百万年龄在5岁以下的儿童严重超重,仅在欧洲联盟内超重的儿童数目预计每年就增加130万个儿童(Kosti等人,2006,Cent.Eur.J.Public Health,14:151-159)。根据大都会人寿保险公司(Metropolitan Life Insurance Co.,)提供的统计公报(1959,40:1)的定义,肥胖症是人们超过正常体重的大约20-25%以上的状态。或者,如果具有风险因子的个人的体重指数大于正常的25%,或大于正常的30%,则个体被认为是肥胖的(见Bray等人,Diabetes/MetabolismReview,1988,4:653-679或Flynn等人,Proc.Nutritional Society,1991,50:413)。肥胖症的一个主要原因是消费高热量的饮食(Riccardi等人,Clin.Nutr.,2004,23:447-456)。
糖尿病是困扰许多超重和肥胖人群的慢性消耗性疾病。据估计仅美国就有二千零八十万人患有糖尿病,还有另外六百万以上是处于未诊断的病例(Cornell,Manag.Care Pharm.,2007,13:S11-5)。2型糖尿病(本文中也称作II型糖尿病)是慢性疾病,其特征是胰岛素抵抗、胰岛素分泌受损和高血糖。在世界范围内,据信II型糖尿病影响大约1.71亿人,引起数目众多的微血管和大血管并发症导致发病和死亡(Mudaliar,Indian J.Med.Res.,2007,125:275-296)。Mudaliar还指出尽管可获得可用的抗高血糖试剂,许多病人中对葡萄糖仍然难以控制。
胰岛素抵抗(也称作胰岛素敏感度降低)是一种病症,其中清除受试者血液中葡萄糖所需的胰岛素的量与正常非胰岛素敏感的受试者血液中清除等量葡萄糖所需的胰岛素的量相比增加了。胰岛素抵抗被认为是肥胖症和II型糖尿病之间的主要联系(见Obici等人,J.Clin.Inv.,2001,108:1079-1085及其中的参考文献)。已知高脂饮食喂养的大鼠显示出体重的增加(饮食诱导肥胖症或DIO),并且胰岛素敏感度降低。这种DIO大鼠提供了研究肥胖症导致的胰岛素抵抗机制的动物模型(参见,例如Banno等人,FEBS letters,2007,581:1131-1136)。在DIO大鼠中脂肪组织的大小和重量增加,人们认为伴随的脂肪细胞的肥大导致脂肪细胞因子(adipocytokine)(如已知调节胰岛素敏感度的瘦蛋白和脂连蛋白)释放的改变;人们认为脂肪组织的形态改变以及血浆脂肪细胞因子水平的改变是DIO大鼠中胰岛素抵抗的原因之一(总结在Banno,等人,FEBS letters,2007,581:1131-1136以及其中的参考文献中)。
人们提出黑皮质素在能量代谢和稳态中发挥巨大作用。黑皮质素从POMC前体剪切而来,通过结合位于脑中的黑皮质素受体家族成员发挥作用。脑中黑皮质素的主要作用是降低食物摄取,然而,也显示当不摄取食物或当食物摄取保持恒定时直接向脑室注射黑皮质素激动剂或拮抗剂影响外周胰岛素的作用(见Schwartz等人,Nature,2000,404:661-671;Seeley等人,Ann.Rev.Nutr.,2004,24:133-149;Cone等人,Recent Prog.Horm.Res.,1996,51:287-317;Heijbor等人,Diabetologia,2005,48:1621-1626;Obici等人,J.Clin.Inv.,2001,108:1079-1085)。总之,这些数据提示中枢施用黑皮质素影响胰岛素敏感度,并且可不依赖于能量平衡而发挥这种作用。Banno等人,(FEBS letters,2007,581:1131-1136)证明向DIO大鼠脑内注射黑皮质素激动剂改善外周胰岛素敏感度,降低白脂肪组织中脂肪细胞的大小并增加其数目,并且降低肝中甘油三酯含量。
考虑到需要治疗的超重和/或胰岛素抵抗受试者的数量众多,脑内施用是不太可能的向患者给药的方式。因此,在本领域中需要鉴定适合通过外周施用的黑皮质素激动剂和拮抗剂来影响胰岛素作用和能量代谢的参数如胰岛素敏感度、白脂肪组织细胞特征、甘油三酯水平等等。
术语和缩写
如本文所用的,“肥胖的受试者”或哺乳动物的特征是对所述受试者来说具有比正常体重多大约20%或更多的体重。正常体重可通过比较该受试者在之前的时间点上(如当胰岛素代谢正常时)的体重,或通过比较该受试者的体重与其他相似年龄和/或状态的受试者之平均体重来确定。
如本文所用的,“超重的受试者”或哺乳动物的特征是对所述受试者来说具有比正常体重多大约5%至多大约20%的体重。正常体重可通过比较该受试者在之前的时间点上(如当胰岛素代谢正常时)的体重,或通过比较该受试者的体重与其他相似年龄和/或状态的受试者之平均体重来确定。
如本文所用的,“正常的受试者”或哺乳动物的特征是对所述受试者来说具有至多比正常体重多大约5%至大约少5%范围的体重。正常体重可通过比较该受试者在之前的时间点上(如当胰岛素代谢正常时)的体重,或通过比较该受试者的体重与其他相似年龄和/或状态的受试者之平均体重来确定。
如本文所用的,“偏瘦的受试者”或哺乳动物的特征是对所述受试者来说具有比正常体重低大约5%至30%或甚至50%的体重。正常体重可通过比较该受试者在之前的时间点上(如当胰岛素代谢正常时)的体重,或通过比较该受试者的体重与其他相似年龄和/或状态的受试者之平均体重来确定。
如本文所用的,术语“治疗(treat、treating和treatment)”包括姑息性、治愈性和预防性治疗。
如本文所用的,“可测量的”的意思是指生物效应既可重复又与该测定的基线变异性有显著差异。
如本文所用的,外周施用包括除了颅内施用之外的其他一切形式的施用本发明的化合物或包含化合物的组合物。外周施用的例子包括但不限于经口、肠胃外(例如,肌内、腹膜内、静脉内或皮下注射、植入等等)、经鼻、阴道、直肠、舌下或者局部施用途径施用,包括透皮贴剂应用等等。
如本文所用和本申请全文所用的,“受试者”是指哺乳动物或非哺乳动物包括,例如,但不限于,人类、大鼠、小鼠或农场动物。提及受试者并不必然表示疾病或病症的存在。术语“受试者”包括,例如作为实验一部分的给予黑皮质素类似物的哺乳动物或非哺乳动物,被治疗以帮助改善疾病或病症的哺乳动物或非哺乳动物,以及被预防性治疗以阻止或预防疾病或病症发生的哺乳动物或非哺乳动物。受试者哺乳动物可以是任何年龄的人类受试者,如婴儿、儿童、成人或老人。
本发明的化合物或组合物的“治疗可接受的量”,不论剂型或施用途径,是引起受试者中合乎需要的生物反应的量。在生物体内,治疗量的生物效应可发生在许多水平并可在许多水平测量。例如,治疗量的生物效应可发生在细胞水平,并可通过测量结合黑皮质素和/或黑皮质素类似物的受体的反应在细胞水平测量,或治疗量的生物效应可发生在全身水平并在全身水平进行测量,如导致胰岛素水平的升高/降低。治疗量的生物效应可发生在生物体水平并在生物体水平测量,如缓解受试者的疾病或状态的症状或进展。本发明的化合物或组合物的“治疗可接受的量”,不论剂型或施用途径,可导致受试者中一种或更多种生物反应。在本发明的化合物或组合物在体外系统中测试的情况下,化合物或组合物的治疗可接受的量可视为在选定体外系统中产生可测量的反应量。
用于定义肽的术语是通常用于本领域的术语,其中N-末端氨基出现在左边,C-末端羧基出现在右边。当氨基酸具有D和L异构形式时,除非明确指出相反,它是所代表氨基酸的L形式。
用于治疗胰岛素抵抗(伴随或不伴随体重减轻)的本发明的化合物可具有一个或更多个手性中心,因此存在许多立体异构形式。所有立体异构体及其混合物包含于本发明的范围中。外消旋化合物可通过制备HPLC和带有手性固定相的柱子分离,或者使用本领域技术人员已知的方法分解以产生单个对映体。此外,可分解手性中间化合物并用其制备本发明的手性化合物。
用于治疗胰岛素抵抗(伴随或不伴随体重减轻)的本发明的化合物可以一种或更多种互变异构形式存在。所有互变异构体及其混合物包含于本发明的范围中。例如要求保护2-羟基吡啶基也覆盖其互变异构形式,α-吡啶酮基。
除非另外定义,本文中使用的所有技术和科学术语具有与本发明所属领域普通技术人员通常理解的相同的含义。而且,本文提到的所有出版物、专利申请、专利和其他参考文献都整体引入本文作为参考。
除非另外指出,除了N-末端氨基酸外,本公开中氨基酸的所有缩写(例如Ala)都代表-NH-C(R)(R′)-CO-的结构,其中R和R’各自独立地为氢或者氨基酸的侧链(例如,对于丙氨酸,R=CH3且R′=H),或者R和R’可以结合形成环体系。
对于N-末端氨基酸,该缩写代表结构:
在例如Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ IDNO:7)中明示的“NH2”表示该肽的C-末端被酰胺化。Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)(SEQ ID NO:36)或备选地Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH(SEQ ID NO:36)表示C-末端是游离酸。
“-c(Cys-Cys)-”或“-环(Cys-Cys)-”表示结构:
“-c(Cys-Pen)-”或“-环(Cys-Pen)-”表示结构:
“-c(Asp-Lys)-”或“-环(Asp-Lys)-”表示结构:
申请人设计了下述速记法用于命名具体实施方案和/或种类(species):
例如,“c[乙内酰脲(C(O)-(Cys-Ab))-A1-A2-A3-A4-Cys]-”表示的化合物将具有下述结构:
而“c[乙内酰脲(C(O)-(Ab-Cys))-A1-A2-A3-A4-Cys]-”表示的化合物将具有结构:
作为进一步的指导,“c[乙内酰脲(C(O)-(Asp-Ab))-A1-A2-A3-A4-Lys]-”
“酰基”指R”-C(O)-,其中R”是H、烷基、被取代的烷基、杂烷基、被取代的杂烷基、烯基、被取代的烯基、芳基、烷基芳基或被取代的烷基芳基,并且在具体实施方案的通式中表示为“Ac”。
“烷基”指含有一个或多个碳原子的烃基,其中多个碳原子(如果存在)通过单键连接。烷基烃基可以是直链或者含有一个或多个支链或者环状基团。
“羟基烷基”指烷基,其中烃基的一个或多个氢原子被一个或多个羟基取代,如羟基甲基、羟基乙基、羟基丙基、羟基丁基、羟基戊基、羟基己基等等。
“被取代的烷基”指烷基,其中烃基的一个或多个氢原子被选自卤素(即,氟、氯、溴和碘)、-OH、-CN、-SH、-NH2、-NHCH3、-NO2和-C1-20烷基的一个或多个取代基取代,其中所述-C1-20烷基任选可以被在每种情况下独立地选自卤素、-CF3、-OCH3、-OCF3和-(CH2)0-20-COOH的一个或多个取代基取代。在不同的实施方案中,存在1、2、3或4个取代基。-(CH2)0-20-COOH的存在导致产生烷基酸。含有或者组成为-(CH2)0-20-COOH的烷基酸的非限制性实例包括2-降冰片烷乙酸、叔丁酸、3-环戊基丙酸,等等。
术语“卤”包括氟、氯、溴和碘。
“杂烷基”指烷基,其中烃基中的一个或多个碳原子被选自下面基团的一个或多个取代:氨基、酰氨基、-O-、-S-或羰基。在不同实施方案中,存在1或2个杂原子。
“被取代的杂烷基”指杂烷基,其中烃基的一个或多个氢原子被选自卤素(即,氟、氯、溴和碘)、-OH、-CN、-SH、-NH2、-NHCH3、-NO2和-C1-20烷基的一个或多个取代基取代,其中所述-C1-20烷基任选可以被在每种情况下独立地选自卤素、-CF3、-OCH3、-OCF3和-(CH2)0-20-COOH的一个或多个取代基取代。在不同实施方案中,存在1、2、3或4个取代基。
“烯基”指由两个或多个碳组成的烃基,其中存在一个或多个碳-碳双键。烯烃基可以是直链或含有一个或多个支链或者环状基团。
“被取代的烯基”指烯基,其中一个或多个氢被选自卤素(即,氟、氯、溴和碘)、-OH、-CN、-SH、-NH2、-NHCH3、-NO2和-C1-20烷基的一个或多个取代基取代,其中所述-C1-20烷基任选可以被在每种情况下独立地选自卤素、-CF3、-OCH3、-OCF3和-(CH2)0-20-COOH的一个或多个取代基取代。在不同实施方案中,存在1、2、3或4个取代基。
“芳基”指具有至少一个环的任选被取代的芳族基团,所述环具有共轭π电子体系,其含有高达三个共轭或稠合的环体系。芳基包括碳环芳基、杂环芳基和联芳基。优选地,芳基是5-或6元环。杂环芳基的优选原子是一个或多个硫、氧和/或氮。芳基的非限制性实例包括苯基、1-萘基、2-萘基、吲哚、喹啉、2-咪唑、9-蒽,等等。芳基取代基选自-C1-20烷基、-C1-20烷氧基、卤素(即,氟、氯、溴和碘)、-OH、-CN、-SH、-NH2、-NO2、被卤素、-CF3、-OCF3、和-(CH2)0-20-COOH取代的-C1-20烷基。在不同实施方案中,芳基含有0、1、2、3或4个取代基。
“烷基芳基”指连接“芳基”的“烷基”。
术语“(C1-C12)烃部分”包括烷基、烯基和炔基,并且在烯基和炔基的情况下,为C2-C12。
为避免疑问,除非另有说明,术语被取代的意思是指被一个或更多个所定义的基团取代。当基团可从许多替代基团中选择的情况下,所选定的基团可以相同或不同。为避免疑问,术语独立地的意思是指当多于一个取代基从许多可能的取代基中选择时,这些取代基可以相同或不同。
含有碱性中心的本发明的化合物的可药用盐是例如无毒性酸加成盐,通过无机酸如盐酸、氢溴酸、氢碘酸、硫酸和磷酸,通过羧酸或通过有机磺酸形成。例子包括HCl、HBr、HI、硫酸盐或硫酸氢盐、硝酸盐、磷酸盐或磷酸氢盐、乙酸盐、苯甲酸盐、琥珀酸盐、蔗糖盐、延胡索酸盐、马来酸盐、乳酸盐、柠檬酸盐、酒石酸盐、葡萄糖酸盐、camsylate、甲磺酸盐、乙磺酸盐、苯磺酸盐、对甲苯磺酸盐和双羟萘酸盐(pamoate salts)。本发明的化合物也提供与碱的可药用金属盐,特别是无毒性碱和碱土金属盐。例子包括钠、钾、铝、钙、镁、锌和二乙醇胺盐(Berge,S.M.等人,J.Pharm.Sci.,66:1-19(1977);Gould,P.L.,Int’l J. Pharmaceutics,33:201-17(1986)和Bighley,L.D.等人,Encyclo.Pharma.Tech.,Marcel Dekker Inc,New York,13:453-97(1996)。
本发明的化合物的可药用溶剂化物包括其水合物。也包含于本发明范围和本发明的多种盐中的是其多形体。此后,本发明任一方面定义的化合物其可药用盐、其溶剂化物或多形体(除了化学过程中的中间化合物)被称为“本发明的化合物”。
体外研究
可以根据下面的方法测试本发明的化合物作为一种或多种黑皮质素受体配体的活性。本领域技术人员将知道类似于本文所述的方法可以用于测定本发明的化合物与黑皮质素受体分子的结合活性。
放射性配体结合测定
从稳定表达hMC-R受体亚型1、3、4或5的转基因CHO-K1细胞得到用于体外受体结合测定的细胞膜。将表达目的hMC-R受体类型的CHO-K1细胞在冰预冷的50mM Tris-HCl(pH 7.4)中超声处理(设置7,约30秒)然后在约4℃下以39,000g离心10分钟。将沉淀物重悬浮在相同的缓冲液中并在约4℃下以50,000g离心10分钟。经洗涤的含有细胞膜的沉淀物保存在约-80℃。
在聚丙烯96孔板中进行[125I](Tyr2)-(Nle4-D-Phe7)α-MSH([125I]-NDP-α-MSH,Amersham)结合的竞争性抑制。将如上述制备的细胞膜(1-10μg蛋白质/孔)在含有0.2%牛血清白蛋白(BSA)、5mMMgCl2、1mM CaCl2和0.1mg/mL杆菌肽与增加浓度的受试化合物和0.1-0.3nM[125I]-NDP-α-MSH的50mM Tris-HCl(pH 7.4)中在约37℃温育约90-120分钟。使用Packard采集器,通过预浸0.1%(w/v)聚乙烯亚胺(PEI)的GF/C玻璃纤维滤板(Packard)过滤分离结合的[125I]-NDP-α-MSH配体与游离的[125I]-NDP-α-MSH。在约0-4℃的温度下用50mM Tris-HCl(pH 7.4)洗涤滤器三次,然后使用Packard闪烁计数器测定放射性。通过计算机辅助的非线性回归分析(XL拟合;IDBS)分析结合数据。使用上述测定法测试一组优选实施方案并且在表5、6、7和8中报告结合常数(Ki,以nM表示)。
表5-所选化合物的放射性配体结合测定数据
表5A
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 | 3.87 | 10.1 | 2.09 | 430 | 1.9 | SEQIDNO:50 |
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 | 4.01 | 12.1 | 1.76 | 352 | 2.3 | SEQIDNO:50 |
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 | 8.29 | 13.3 | 2.78 | 816 | 3.0 | SEQIDNO:51 |
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 | 3.93 | 172 | 11.0 | 538 | 0.36 | SEQIDNO:52 |
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 | 1.81 | 20.5 | 4.57 | 502 | 0.4 | SEQIDNO:52 |
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 | 9.67 | 22.0 | 4.2 | 1900 | 2.3 | SEQIDNO:51 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2 | 0.79 | 45.5 | 1.21 | 493 | 0.6 | SEQIDNO:53 |
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2 | 0.68 | 20.7 | 1.01 | 783 | 0.7 | SEQIDNO:53 |
表5B
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2 | 114 | 63.9 | 3.07 | 1657 | 37.1 | SEQIDNO:16 |
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-NH2 | 11 | 26 | 7.6 | 1800 | 1.4 | SEQIDNO:7 |
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 | 0.05 | 9.3 | 1.1 | 2.9 | 0.0 | SEQIDNO:24 |
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2 | 0.07 | 4.1 | 0.85 | 8.8 | 0.1 | SEQIDNO:27 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 | 0.12 | 10 | 0.43 | 0.42 | 0.3 | SEQIDNO:32 |
Nle-c(Cys-His-D-Ph e-Arg-Trp-Gaba-Cys)-NH2 | 0.05 | 1.3 | 0.47 | 0.2 | 0.1 | SEQIDNO:34 |
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2 | 0.0996 | 9318 | 0.617 | 10.9 | 0.16 | SEQIDNO:1 |
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2 | .0132 | 16.1 | 1.23 | 0.359 | 0.11 | SEQIDNO:2 |
D-Ph e-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 | 0.207 | 43.2 | 2.58 | 344 | 0.08 | SEQIDNO:3 |
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2 | 0.420 | 106 | 4.75 | 1260 | 0.09 | SEQIDNO:3 |
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2 | 0.0951 | 9.33 | 0.894 | 13.4 | 0.11 | SEQIDNO:2 |
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2 | 0.999 | 300 | 11.1 | 431 | 0.09 | SEQIDNO:4 |
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Ga ba-Lys)-NH2 | 0.106 | 11.8 | 1.49 | 110 | 0.07 | SEQIDNO:6 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Gaba-Lys)-NH2 | 0.0506 | 9.89 | 1.04 | 16.3 | 0.05 | SEQIDNO:6 |
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2 | 0.884 | 223 | 22.5 | 609 | 0.04 | SEQIDNO:11 |
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2 | 0.721 | 93.5 | 56.0 | 747 | 0.01 | SEQIDNO:11 |
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2 | 0.227 | 14.5 | 2.99 | 164 | 0.08 | SEQIDNO:11 |
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Ga ba-Lys)-NH2 | 0.277 | 25.2 | 3.37 | 203 | 0.08 | SEQIDNO:11 |
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2 | 0.323 | 14.1 | 1.96 | 24.0 | 0.16 | SEQIDNO:15 |
Ac-Nle-c(Pen-D-Ala-His-D-Ph e-Arg-Trp-Cys)-NH2 | 34.1 | 118 | 17.0 | 5560 | 2.01 | SEQIDNO:21 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 | 29.1 | 22.8 | 3.84 | 2550 | 7.58 | SEQIDNO:22 |
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2 | 0.442 | 123 | 10.3 | 521 | 0.04 | SEQIDNO:23 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2 | 5.80 | 3370 | 583 | 1130 | 0.01 | SEQIDNO:25 |
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2 | 0.0567 | 31.4 | 14.7 | 9.27 | 0 | SEQIDNO:24 |
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2 | 1.68 | 1260 | 172 | 1220 | 0.01 | SEQIDNO:26 |
D-Ph e-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2 | 0.128 | 85.6 | 36.9 | 38.0 | 0 | SEQIDNO:26 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2 | 0.352 | 149 | 3.01 | 339 | 0.12 | SEQIDNO:54 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2 | 3.93 | 876 | 48.0 | 4940 | 0.08 | SEQIDNO:54 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2 | 0.995 | 287 | 4.80 | 766 | 0.21 | SEQIDNO:54 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.848 | 184 | 3.76 | 956 | 0.23 | SEQIDNO:54 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2 | 1.10 | 228 | 7.58 | 859 | 0.15 | SEQIDNO:54 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Nle-c(Asp-D-Ala-His-D-Ph e-Arg-Trp-Lys)-NH2 | 0.659 | 98.9 | 2.55 | 4.19 | 0.26 | SEQIDNO:28 |
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2 | 4.12 | 445 | 50.6 | 4300 | 0.08 | SEQIDNO:28 |
Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2 | 111 | 1710 | 47.7 | 694 | 2.33 | SEQIDNO:55 |
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2 | 262 | 2500 | 96.4 | 1460 | 2.72 | SEQIDNO:55 |
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2 | 199 | 5990 | 96.7 | >10000 | 2.06 | SEQIDNO:56 |
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2 | 132 | 4560 | 40.7 | 8810 | 3.24 | SEQIDNO:56 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2 | 9.12 | 1130 | 22.1 | 2860 | 0.41 | SEQIDNO:57 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2 | 1.00 | 227 | 5.55 | 496 | 0.18 | SEQIDNO:57 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.536 | 169 | 3.12 | 358 | 0.17 | SEQIDNO:57 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH | 32.1 | 330 | 17.4 | 165 | 1.84 | SEQIDNO:29 |
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2 | 10.6 | 41.1 | 7.69 | 54.9 | 1.38 | SEQIDNO:30 |
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2 | 13.0 | 104 | 10.1 | 40 | 1.29 | SEQIDNO:30 |
Ac-Nle-c(Cys-D-Ile-His-D-Ph e-Arg-Trp-Cys)-NH2 | 4.28 | 38.5 | 9.0 | 12.5 | 0.48 | SEQIDNO:30 |
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2 | 1.60 | 6.82 | 4.13 | 5.57 | 0.39 | SEQIDNO:30 |
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2 | 12.0 | 85.8 | 11.2 | 40 | 1.07 | SEQIDNO:30 |
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2 | 0.353 | 2.08 | 1.41 | 0.857 | 0.25 | SEQIDNO:30 |
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.537 | 86.1 | 5.89 | 2.56 | 0.09 | SEQIDNO:31 |
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 | 0.744 | 178 | 3.51 | 2.69 | 0.21 | SEQIDNO:32 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.216 | 17.4 | 0.995 | 0.486 | 0.22 | SEQIDNO:33 |
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.107 | 9.11 | 0.884 | 0.354 | 0.12 | SEQIDNO:33 |
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.148 | 13.9 | 1.06 | 0.423 | 0.14 | SEQIDNO:33 |
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.254 | 18.5 | 2.13 | 0.714 | 0.12 | SEQIDNO:33 |
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.256 | 29.9 | 1.98 | 0.864 | 0.13 | SEQIDNO:33 |
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.560 | 39.2 | 2.94 | 2.73 | 0.19 | SEQIDNO:33 |
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.186 | 15.2 | 4.93 | 0.537 | 0.04 | SEQIDNO:34 |
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 21.1 | 151 | 10.4 | 92.6 | 2.03 | SEQIDNO:35 |
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-OH | 30.7 | 152 | 15.6 | 114 | 1.97 | SEQIDNO:36 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2 | 5.20 | 150 | 138 | 20.3 | 0.04 | SEQIDNO:37 |
Ac-Nle-c(Asp-D-Ala-His-D-Ph e-Arg-Bal-Ala-Lys)-NH2 | 4.89 | 290 | 21.3 | 11.1 | 0.23 | SEQIDNO:58 |
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 | 25.5 | 3.82 | 7.61 | 102 | 3.35 | SEQIDNO:16 |
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2 | 32.5 | 5.85 | 2.53 | 94.6 | 12.85 | SEQIDNO:16 |
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2 | 22.2 | 12.7 | 16.6 | 125 | 1.34 | SEQIDNO:20 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2 | 1.17 | 1.56 | 0.277 | 3.24 | 4.22 | SEQIDNO:38 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2 | 0.648 | 2.78 | 0.329 | 1.4 | 1.97 | SEQIDNO:38 |
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2 | 0.393 | 1.86 | 0.375 | 1.11 | 1.05 | SEQIDNO:39 |
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2 | 0.333 | 2.91 | 0.998 | 0.366 | 0.33 | SEQIDNO:39 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2 | 0.461 | 2.45 | 0.931 | 1.37 | 0.50 | SEQIDNO:40 |
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2 | 0.576 | 3.98 | 2.82 | 3.91 | 0.20 | SEQIDNO:40 |
表5C
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R | KihMC1-R/MC4-R | SEQID NO: |
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 | 17.9 | 1.68 | 0.256 | 23.4 | 69.9 | SEQIDNO:49 |
表6-所选化合物的放射性配体结合测定数据
表6A
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-GKu-His-D-2-Nal-Arg/Trp-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:269) | 49.9 | 9.00 | 0.569 | 218 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2(SEQ ID NO:60) | 11.9 | 38.1 | 5.70 | 11.8 |
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2(SEQ ID NO:61) | 3.46 | 16.6 | 6.65 | 4.88 |
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:62) | 0.614 | 5.09 | 2.31 | 3.23 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:62) | 1.56 | 14.1 | 5.17 | 7.12 |
H-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Doc-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:63) | 1.10 | 1.58 | 6.00 | 0.629 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:64) | 0.0868 | 0.751 | 0.0944 | 0.147 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:65) | 1.66 | 4.80 | 0.250 | 9.62 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:66) | 0.0452 | 0.298 | 0.169 | 0.386 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:67) | 0.0808 | 0.396 | 0.0747 | 0.311 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:68) | 4.41 | 4.23 | 0.455 | 12.9 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 1.25 | 0.661 | 0.292 | 5.94 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 1.89 | 0.546 | 0.166 | 6.06 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:269) | 87.8 | 9.08 | 1.20 | 359 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:269) | 124 | 17.8 | 1.11 | 348 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:269) | 163 | 23.0 | 0.586 | 844 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Doc-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:701) | 0.144 | 0.352 | 0.0845 | 0.415 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 1.74 | 0.590 | 0.170 | 4.38 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:83) | 3.86 | 4.97 | 0.192 | 38.3 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:73) | 12.8 | 15.9 | 0.950 | 165 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:74) | 3.07 | 4.05 | 0.498 | 31.1 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-βAla-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:75) | 0.792 | 0.570 | 0.162 | 4.18 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Gln-Arg-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:76) | 0.726 | 0.474 | 0.209 | 5.12 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-Arg-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:77) | 0.857 | 0.580 | 0.209 | 4.42 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Arg-Arg-Gln-Arg-NH2(SEQ ID NO:78) | 0.813 | 0.675 | 0.269 | 4.20 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Aib-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:79) | 7.84 | 10.2 | 0.783 | 91.8 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:80) | 2.93 | 9.07 | 0.293 | 59.0 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:80) | 2.42 | 6.56 | 0.238 | 41.7 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:81) | 6.66 | 19.3 | 0.819 | 88.8 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:82) | 2.63 | 2.09 | 0.0737 | 11.6 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:82) | 2.48 | 1.21 | 0.209 | 9.17 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:81) | 3.65 | 2.26 | 0.261 | 12.1 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:83) | 7.32 | 11.0 | 0.659 | 78.0 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:84) | 4.11 | 7.26 | 0.302 | 48.3 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:283) | 6.77 | 14.3 | 0.781 | 84.0 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Arg-Gln-Arg-Arg-NH2(SEQ ID NO:2685) | 3.04 | 3.22 | 0.230 | 3.85 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Gln-Lys-Lys-Arg-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:86) | 3.24 | 2.66 | 0.208 | 5.96 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Arg-Arg-Arg-Gln-NH2(SEQ ID NO:87) | 1.58 | 1.43 | 0.275 | 2.97 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 4.59 | 6.28 | 0.588 | 22.6 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 6.46 | 5.22 | 0.380 | 15.3 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:88) | 4.62 | 5.68 | 0.505 | 45.3 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:89) | 2.12 | 3.99 | 0.352 | 27.5 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:88) | 3.41 | 0.975 | 0.549 | 11.3 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:90) | 4.18 | 1.12 | 0.223 | 15.3 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:91) | 2.71 | 0.732 | 0.202 | 5.53 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:92) | 5.66 | 1.40 | 0.446 | 6.23 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:136) | 0.211 | 0.665 | 0.635 | 118 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Arg-NH2(SEQ IDNO:137) | 0.351 | 0.891 | 0.503 | 102 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:136) | 0.209 | 0.699 | 0.596 | 137 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:138) | 0.439 | 1.52 | 0.476 | 115 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:138) | 0.821 | 2.50 | 0.700 | 148 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:139) | 0.406 | 1.11 | 0.602 | 131 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-Arg-NH2(SEQ IDNO:139) | 1.27 | 4.63 | 1.51 | 220 |
表6B
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-β-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:270) | 2058 | 113 | 10.7 | 239 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:270) | 1818 | 306 | 5.87 | 979 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:95) | 1.75 | 1.74 | 0.15 | 16.8 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:96) | 1.50 | 1.61 | 0.301 | 10.4 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:97) | 1.81 | 2.08 | 0.305 | 19.3 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:92) | 2.69 | 2.59 | 0.243 | 19.2 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:99) | 2.25 | 0.62 | 0.303 | 2.77 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:101) | 1.49 | 0.604 | 0.865 | 3.13 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:105) | 3.28 | 1.95 | 0.575 | 15.5 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:100) | 2.24 | 1.57 | 0.437 | 16.4 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:101) | 2.14 | 1.12 | 0.624 | 11.9 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:102) | 2.50 | 1.59 | 0.573 | 15.7 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:104) | 3.00 | 1.70 | 0.442 | 15.5 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:103) | 4.29 | 2.15 | 0.425 | 15.5 |
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:141) | 0.410 | 0.837 | 0.246 | 56.3 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:142) | 0.572 | 1.07 | 0.210 | 63.6 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:141) | 0.475 | 0.800 | 0.196 | 53.8 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:142) | 0.779 | 1.21 | 0.293 | 56.0 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:143) | 0.212 | 1.23 | 0.484 | 58.5 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:144) | 0.778 | 1.22 | 0.468 | 47.0 |
表7-通式(V)例子的结合常数
表7A
通式(V)的化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:271) | 230 | 7590 | 126 | 7020 |
通式(V)的化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2(SEQ ID NO:276) | 72.6 | 1920 | 45.2 | >10000 |
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2(SEQ ID NO:276) | 60.4 | 2840 | 52.4 | >10000 |
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2(SEQ ID NO:276) | 28 | 90.5 | 12.7 | 877 |
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2(SEQ ID NO:276) | 16.4 | 863 | 4.97 | >10000 |
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2(SEQ ID NO:273) | 37.7 | 576 | 7.81 | 6400 |
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2(SEQ ID NO:273) | 66.6 | 1820 | 19.9 | >10000 |
c[乙内酰脲(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ ID NO:275) | 200 | 68.8 | 6.63 | 142 |
c[乙内酰脲(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ ID NO:275) | 9028 | 2628 | 35.8 | 1156 |
c[乙内酰脲(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ ID NO:275) | 9938 | 2390 | 44.6 | 1103 |
通式(V)的化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
c[乙内酰脲(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ ID NO:275) | 2170 | 1479 | 16.5 | 451 |
c[乙内酰脲(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ ID NO:275) | 1276 | 2756 | 266 | 1096 |
c[乙内酰脲(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ ID NO:275) | 7567 | 1922 | 420 | 2879 |
表7B-通式(VI)例子的结合常数
通式(VI)的化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 14.3 | 198 | 5.76 | 67.8 |
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 11.9 | 311 | 5.41 | 73.9 |
乙内酰脲(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | 31.6 | 224 | 19.6 | 2500 |
乙内酰脲(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | 16.0 | 63.9 | 8.64 | 1820 |
通式(VI)的化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
乙内酰脲(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | 33.7 | 132 | 40.2 | 3210 |
乙内酰脲(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | 48.3 | 534 | 74.1 | 3290 |
乙内酰脲(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | 40.8 | 870 | 137 | 3560 |
乙内酰脲(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | 17.7 | 73.6 | 8.40 | 2120 |
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 7.92 | 46.4 | 6.70 | 21.3 |
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 20.9 | 69.7 | 8.32 | 50.0 |
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2(SEQ ID NO:280) | 12.9 | 38.5 | 3.53 | 27.1 |
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2(SEQ ID NO:280) | 127 | 811 | 10.4 | 381 |
乙内酰脲(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 13.9 | 38.4 | 5.73 | 18.9 |
通式(VI)的化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
乙内酰脲(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 11.7 | 73.1 | 4.28 | 34.7 |
乙内酰脲(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 36.8 | 290 | 13.7 | 133 |
乙内酰脲(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 15.3 | 160 | 8.66 | 33.4 |
乙内酰脲(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 11.6 | 194 | 11.5 | 28.9 |
乙内酰脲(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SE Q ID NO:279) | 19.3 | 331 | 26.7 | 44.6 |
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 9.49 | 124 | 2.95 | 2260 |
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:287) | 4.30 | 78.0 | 1.77 | 4540 |
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 8.59 | 94.1 | 2.44 | 7760 |
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:285) | 5.68 | 55.5 | 2.44 | 4220 |
通式(VI)的化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 2.65 | 41.3 | 4.17 | 650 |
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 3.52 | 48.7 | 5.78 | 872 |
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO288) | 3.51 | 29.2 | 6.04 | 914 |
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:286) | 1.14 | 01.7 | 4.53 | 783 |
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2(SEQ ID NO:282) | 11.9 | 7.43 | 0.195 | 14.6 |
表7C-通式(VII)例子的结合常数
通式(VII)化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
c[乙内酰脲(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | 47.6 | 1100 | 47.1 | >10000 |
c[乙内酰脲(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | 21.2 | 730 | 34.5 | >10000 |
通式(VII)化合物 | KihMC1 | KihMC3 | KihMC4 | KihMC5 |
c[乙内酰脲(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | 47.4 | 1550 | 27.9 | >10000 |
c[乙内酰脲(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | 53.4 | 1760 | 41.6 | >10000 |
c[乙内酰脲(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | 38.5 | 1760 | 53.2 | 9270 |
c[乙内酰脲(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:291) | 15.6 | 305 | 8.92 | 3070 |
表8-所选化合物的放射性配体结合测定数据
化合物 | KihMC1-R | KihMC3-R | KihMC4-R | KihMC5-R |
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 8.53 | 21.2 | 3.72 | 714 |
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 6.09 | 34.9 | 2.02 | 864 |
Ac-1-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 6.27 | 36.4 | 1.53 | 888 |
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 1.48 | 14.8 | 2.34 | 491 |
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 4.7 | 42 | 2.25 | 1470 |
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 0.323 | 1.33 | 1.95 | 786 |
黑皮质素功能活性和选择性
相对于其他黑皮质素受体,本发明的化合物将优先(即选择性地)与MC-4相互作用。当化合物施用于人类或其他动物时,为使与他们的施用相关的副作用的数量最小,选择性是特别重要的。本文中化合物的MC-4选择性定义为化合物对MC-1受体的EC50(EC50-MC-1)与化合物对MC-3(EC50-MC-3)/MC-4(EC50-MC-4)受体的EC50的比率,EC50值如上所述进行测量。公式如下:
MC-3选择性=[EC50-MC-1]/[EC50-MC-3]
MC-4选择性=[EC50-MC-1]/[EC50-MC-4]
当上述比率“MC-3-选择性”为至少大约10,优选地至少大约100,更优选地至少大约500时,化合物在本文中被定义为是“对MC-3受体选择性的”。
当上述比率“MC-4-选择性”为至少大约10,优选地至少大约100,更优选地至少大约500时,化合物在本文中被定义为是“对MC-4受体选择性的”。
本领域技术人员应知道如本文描述的相似的方法可用于测定本发明的化合物对黑皮质素受体分子的结合活性。
环AMP生物测定
通过电化学发光(ECL)测定法(Meso ScaleGaithersburg,MD;下文中称作MSD)测定细胞内环AMP(cAMP)水平。将稳定表达hMC受体亚型的CHO-K1细胞悬浮在RMPI测定缓冲液中(RMPI 1640缓冲液含有0.5mM异丁基甲基黄嘌呤(IBMX),和0.2%蛋白质混合物(MSD阻断剂A))。将稳定表达hMC受体亚型1、3、4或5的转基因CHO-K1细胞以约7,000个细胞/孔的密度分配在384-孔Multi-平板(MSD)中,该平板含有集成的碳电极并且用抗-cAMP抗体包被。加入递增浓度的受试化合物并将细胞在约37℃温育约40分钟。该温育后,加入含有0.2%蛋白质混合物和2.5nM TAGTM钌标记的cAMP(MSD)的裂解缓冲液(含有MgCl2和Triton的HEPES缓冲的盐溶液,ph 7.3)并将细胞在室温下温育约90分钟。第二次温育期结束时,加入读数缓冲液(含有ECL共反应剂和Triton X-100的Tris缓冲液,ph 7.8)并用Sector Imager 6000(MSD)通过ECL检测立即测定细胞裂解物中的cAMP水平。使用计算机辅助的非线性回归分析(XL拟合;IDBS)分析数据并报告为EC50值或Kb值。
EC50代表得到50%的最大反应应答,例如,如使用上述测定法测定的cAMP的50%最大水平所需的激动剂化合物浓度。Kb值反映了拮抗剂的潜能并且通过Schild分析测定。简言之,在递增浓度的拮抗剂存在下进行激动剂的浓度反应曲线。Kb值是在激动剂的浓度反应曲线中将产生两倍偏移的拮抗剂浓度。通过将Schild曲线上的线外推到y轴上的0计算Kb。
使用上述测定法测试一组化合物并且结果在表9、10、11和12中报告。
表9-所选化合物的cAMP生物测定数据
表9A
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R | EC50hMC1-R/MC4-R | SEQIDNO: |
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 | 5.79 | 5.25 | 0.313 | 1630 | 18.0 | SEQIDNO:50 |
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 | 6.17 | 5.6 | 0.397 | 1020 | 16.0 | SEQIDNO:50 |
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R | EC50hMC1-R/MC4-R | SEQIDNO: |
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 | 26.5 | 10.5 | 0.493 | 2440 | 54.0 | SEQIDNO:51 |
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 | 8.43 | 32.4 | 0.959 | 2140 | 9.0 | SEQIDNO:52 |
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 | 4.23 | 8.09 | 0.719 | 23.2 | 6.0 | SEQIDNO:52 |
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 | 48.3 | 13.3 | 0.79 | 10000 | 61.0 | SEQIDNO:51 |
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2 | 1.48 | 5.76 | 0.078 | 297 | 19.0 | SEQIDNO:53 |
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2 | 1.39 | 2.89 | 0.055 | 467 | 25.0 | SEQIDNO:53 |
ND=未测定
表9B
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R | EC50hMC1-R/MC4-R | SEQIDNO: |
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R | EC50hMC1-R/MC4-R | SEQIDNO: |
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-NH2 | 2.4 | 0.33 | 0.078 | 420 | 31 | SEQIDNO:7 |
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 | 0.35 | 1.1 | 0.11 | 0.37 | 3 | SEQIDNO:24 |
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-NH2 | 0.31 | 0.27 | 0.018 | 3.1 | 17 | SEQIDNO:27 |
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 | 0.28 | 0.24 | 0.028 | 3.9 | 10 | SEQIDNO:32 |
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2 | 0.37 | 0.1 | 0.021 | 1.7 | 18 | SEQIDNO:34 |
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2 | 0.834 | 0.145 | 0.128 | 2.79 | 6.52 | SEQIDNO:1 |
Ac-Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-NH2 | 0.76 | 0.199 | 0.0492 | 1.73 | 15.45 | SEQIDNO:2 |
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2 | 3.26 | 0.189 | 0.0949 | 30.2 | 34.35 | SEQIDNO:6 |
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Gaba-Lys)-NH2 | 1.37 | 0.628 | 0.131 | 3.48 | 10.46 | SEQIDNO:6 |
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R | EC50hMC1-R/MC4-R | SEQIDNO: |
Ac-h C h a-c(Asp-His-D-Ph e-Arg-Trp-Gaba-Lys)-NH2 | 2.27 | 3.32 | 7.24 | 415 | 0.31 | SEQIDNO:11 |
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 | ND | 1.89 | 0.531 | ND | ND | SEQIDNO:21 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 | 14.3 | 2.03 | 0.183 | 2240 | 78.14 | SEQIDNO:22 |
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2 | 0.345 | 2.71 | 5376 | 2.38 | 0.06 | SEQIDNO:24 |
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2 | 0.685 | 81.8 | 86.9 | 31.8 | 0.01 | SEQIDNO:26 |
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2 | 0.931 | 3.22 | 1.65 | >10000 | 0.56 | SEQIDNO:28 |
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2 | 3.24 | 0.465 | 0.0915 | 78.5 | 35.41 | SEQIDNO:30 |
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2 | 0.819 | 0.541 | 0.453 | 45.3 | 1.81 | SEQIDNO:30 |
ND=未测定
表9C
化合物 | EC50hMC1-R | KbhMC3-R | KbMC4-R | EC50hMC5-R | SEQIDNO: |
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 | 17.6 | 12.4 | 38.8 | 11.8 | SEQIDNO:16 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2 | 0.619 | 2.98 | 0.109 | 0.189 | SEQIDNO:38 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2 | 0.913 | 0.536 | 0.346 | 0.489 | SEQIDNO:38 |
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2 | 0.231 | 18.4 | 0.782 | 0.153 | SEQIDNO:39 |
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2 | 0.581 | 10.8 | 0.967 | 0.126 | SEQIDNO:39 |
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2 | 0.413 | 9.32 | 0.824 | 0.307 | SEQIDNO:40 |
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2 | 1.27 | 3.02 | 0.442 | 0.736 | SEQIDNO:40 |
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2 | 383 | 61.5 | 53.6 | 2842 | SEQIDNO:16 |
表9D
化合物 | EC50hMC1-R | KbhMC3-R | KbMC4-R | EC50hMC5-R | SEQIDNO: |
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 | 193 | 5.72 | 1.58 | 1111 | SEQIDNO:49 |
表10A
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:269) | 66.1 | 33.4 | 0.687 | 6.84 |
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2(SEQ ID NO:60) | ND | 4500 | 105 | ND |
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2(SEQ ID NO:61) | ND | 395 | 16.8 | ND |
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:62) | ND | 207 | 18.5 | ND |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:62) | ND | 220 | 4.07 | ND |
H-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Doc-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:63) | ND | 261 | 3.11 | ND |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:64) | ND | 14.1 | 22.8 | ND |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:65) | ND | 233 | 26.0 | ND |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:66) | 1.39 | 16.2 | 7.94 | 0.839 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:67) | 3.65 | 19.4 | 3.73 | 1.61 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:68) | ND | 17.7 | 1.49 | ND |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:69) | 6.3 | 70.0 | 1.66 | 38.2 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:69) | 12.1 | 30.3 | 1.81 | 70.0 |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:269) | 33.6 | 140 | 12.2 | 66.9 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:269) | 269 | 105 | 5.92 | 104 |
Ac-cCys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ ID NO:269) | 690 | 70.7 | 4.56 | 177 |
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Doc-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:70) | 3.23 | 8.97 | 4.61 | 2.86 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:72) | 52.0 | 170 | 6.14 | 328 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:73) | 146 | 104 | 32.0 | 1400 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:74) | 114 | 44.6 | 28.4 | 879 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Aib-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:79) | 67.1 | 439 | 46.5 | 582 |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:80) | 144 | 116 | 8.93 | 819 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:80) | 36.0 | 46.5 | 11.4 | 56.1 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:81) | 93.0 | 71 | 15.9 | >10000 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:82) | 39.7 | 30.9 | 6.66 | 501 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:82) | 35.2 | 22.9 | 12.6 | 199 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:81) | 29.1 | 13.6 | 13.4 | 204 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:83) | 86.1 | 41.7 | 19.4 | 2360 |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Arg-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:84) | 38.3 | 20.2 | 21.2 | >10000 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:83) | 68.6 | 153 | 33.2 | >10000 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:88) | 70.4 | 286 | 18.6 | >10000 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:89) | 33.1 | 65.1 | 15.3 | 1720 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:88) | 88.2 | 10.6 | 17.4 | 514 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:90) | 58.7 | 39.3 | 10.3 | 460 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:91) | 45.4 | 12.7 | 12.7 | 162 |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:92) | 309 | 22.8 | 17.1 | 570 |
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:139) | 7.86 | 10.5 | 0.843 | 4900 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 29.7 | 25.6 | 7.37 | 82.9 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-βAla-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:75) | 15.2 | 14.6 | 4.52 | 36.8 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Gln-Arg-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:76) | 6.7 | 9.38 | 11.7 | 46.2 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-Arg-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:77) | 7.9 | 41.7 | 10.9 | 62.4 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Arg-Arg-Gln-Arg-NH2(SEQ ID NO:78) | 16.9 | 36.0 | 7.12 | 58.9 |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Arg-Gln-Arg-Arg-NH2(SEQ ID NO:85) | 16.4 | 20.8 | 7.31 | 44.2 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Gln-Lys-Lys-Arg-Arg-Arg-Arg-Arg-NH2(SEQ ID NO:86) | 12.0 | 13.7 | 9.38 | 54.2 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Arg-Arg-Arg-Gln-NH2(SEQ ID NO:87) | 7.5 | 12.2 | 7.61 | 51.7 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 43.3 | 215 | 5.87 | 1286 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:71) | 37.9 | 112 | 41.1 | 1798 |
ND=未测定
表10B
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:136) | 4.70 | 4.56 | 0.634 | 147 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Arg-NH2(SEQ IDNO:137) | 5.90 | 7.73 | 1.02 | 2890 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:136) | 0.481 | 7.32 | 0.964 | 2010 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:138) | 7.15 | 9.37 | 1.25 | 1570 |
表10C
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-β-Ala-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:270) | ND | ND | ND | ND |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-Pro-Pro-Lys-Asp-NH2(SEQ IDNO:270) | 770 | 221 | 4.52 | 869 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:95) | 29 | 22.6 | 16.7 | 173 |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:96) | 102 | 26.3 | 14.6 | 261 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:97) | 26.6 | 101 | 9.34 | 351 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:92) | 45.5 | 181 | 6.35 | 149 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQID NO:99) | 23.7 | 9.22 | 5.87 | 39.7 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:101) | 34.7 | 15.0 | 8.68 | 28.2 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:105) | 19.1 | 106 | 4.59 | 100 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:100) | 19.8 | 37.8 | 8.43 | 158 |
化合物 | EC50hMC1-R | KbhMC3-R | KbhMC4-R | EC50hMC5-R |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:101) | 11.2 | 52.1 | 9.45 | 95.7 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:102) | 33.8 | 93.6 | 4.42 | 89.5 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:104) | 232 | 68.8 | 10.0 | 250 |
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-Pro-Pro-Lys-Asp-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:103) | 32.2 | 98.3 | 5.23 | 194 |
ND=未测定
表10D
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:141) | 5.66 | 4.70 | 0.422 | 1551 |
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R |
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ IDNO:142) | 7.57 | 4.18 | 0.600 | 1792 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:141) | 2.36 | 2.74 | 0.260 | 500 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:142) | 2.81 | 3.29 | 0.298 | 566 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:143) | 1.86 | 1.39 | 0.367 | 165 |
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH2(SEQ ID NO:144) | 2.06 | 1.61 | 0.394 | 199 |
表11-通式(I)例子的细胞内环AMP(cAMP)水平
表11A
通式(V)化合物 | EC50hMC1 | EC50hMC3 | EC50hMC4 | EC50hMC5 |
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:271) | - | 218 | 5.42 | - |
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2(SEQ ID NO:276) | - | 22.3 | 3.62 | - |
通式(V)化合物 | EC50hMC1 | EC50hMC3 | EC50hMC4 | EC50hMC5 |
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2(SEQ ID NO:276) | - | 39.2 | 4.94 | - |
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2(SEQ ID NO:276) | 56.7 | 18.2 | 0.182 | >10000 |
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2(SEQ ID NO:273) | 56.6 | 88.6 | 4.50 | 9300 |
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2(SEQ ID NO:273) | - | 49.3 | 2.12 | - |
表11B-
通式(VI)化合物 | EC50hMC1 | EC50hMC3 | EC50hMC4 | EC50hMC5 |
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 54.3 | 12.2 | 0.177 | >10000 |
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 124 | 8.05 | 0.214 | >10000 |
乙内酰脲(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | - | 4.89 | 1.80 | - |
通式(VI)化合物 | EC50hMC1 | EC50hMC3 | EC50hMC4 | EC50hMC5 |
乙内酰脲(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | - | 2.56 | 1.47 | - |
乙内酰脲(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | - | 4.61 | 0.977 | - |
乙内酰脲(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | - | 9.68 | 1.83 | - |
乙内酰脲(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:284) | - | 9.97 | 13.9 | - |
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 14.2 | 2.46 | 0.336 | 201 |
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2(SEQ ID NO:280) | 17.0 | 21.5 | 0.584 | 352 |
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2(SEQ ID NO:280) | 40.2 | 8.90 | 0.495 | 8300 |
乙内酰脲(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 17.6 | 2.23 | 0.241 | 516 |
乙内酰脲(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 4.70 | 2.22 | 0.309 | 355 |
通式(VI)化合物 | EC50hMC1 | EC50hMC3 | EC50hMC4 | EC50hMC5 |
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 18.0 | 17.1 | 0.160 | 2710 |
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:287) | 12.9 | 10.3 | 0.125 | 7440 |
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) | 8.83 | 7.86 | 0.0979 | 4010 |
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:285) | 9.97 | 3.63 | 0.0687 | 335 |
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 8.81 | 18.2 | 0.503 | 3560 |
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:279) | 11.5 | 23.2 | 0.513 | 3950 |
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:288) | 7.53 | 11.6 | 0.435 | 9840 |
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:286) | 8.85 | 5.17 | 0.599 | 3610 |
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Na1-Arg-Trp-Cys)-NH2(SEQ ID NO:282) | 96.6 | 13.1 | 21.2 | 103 |
表11C
通式(VII)的化合物 | EC50hMC1 | EC50hMC3 | EC50hMC4 | EC50hMC5 |
c[乙内酰脲(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | - | 6.28 | 0.407 | - |
c[乙内酰脲(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | - | 3.77 | 0.214 | - |
c[乙内酰脲(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | - | 4.72 | 0.428 | - |
c[乙内酰脲(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | - | 8.51 | 1.85 | - |
c[乙内酰脲(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:290) | - | 5.66 | 1.72 | - |
c[乙内酰脲(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2(SEQ ID NO:291) | 14.5 | 21.8 | 0.576 | 1780 |
表12-所选化合物的cAMP生物测定数据
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R |
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 6.42 | 2.39 | 0.194 | 1540 |
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 9.66 | 6.11 | 0.275 | 1730 |
化合物 | EC50hMC1-R | EC50hMC3-R | EC50hMC4-R | EC50hMC5-R |
Ac-1-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 8.67 | 4.21 | 0.363 | 1320 |
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:292) | 5.78 | 3.95 | 0.219 | 2580 |
体内研究
可以根据下面的方法测试本发明的化合物对胰岛素抵抗和/或体重的影响。本领域技术人员将理解与本文所述的相似的方法可以用于测定本发明的化合物对胰岛素抵抗和/或体重的影响。
在体内研究中测试的激活黑皮质素受体的配体化合物如下(表13):
表13
配体代码 | 结构 |
化合物A | Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ IDNO:50 |
化合物B | 乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:278) |
急性喂饲实验(禁食)
将雄性Sprague Dawley大鼠(250g)放在单独的笼子中并在12:12小时光:暗条件下维持。在开始实验前将大鼠禁食18小时,可以自由引水。在时间0时,将大鼠用所选化合物以100nmole/kg的剂量或者用载体皮下(sc)注射,并提供食物。注射后约2、4和6小时测量个体食物消耗。在图1中报告本发明的所选化合物的数据。
慢性喂饲实验
将雄性Sprague Dawley大鼠(在开始实验前已经用正常饮食(300g;Research Diets 12450)或高脂饮食(400g;Research Diets 12451)喂养10周)放在单独的笼子中并在12:12小时光:暗条件下维持,自由获得食物和水。麻醉大鼠并皮下植入渗透迷你泵(Alzet,Cupertino,CA)。该泵递送化合物A或化合物B(剂量为75、300或1200nmole/kg/天)或载体7天。每天测量个体体重和食物消耗。
在第7天麻醉大鼠并插颈静脉-右心房插管。在第8天进行静脉内葡萄糖耐量试验,在时间-10和0时抽取血液样品到肝素化的注射器中。在时间0时采取血液标本之后,马上通过内在插管对大鼠注射葡萄糖(1g/kg)。在2.5、5、10、20和40分钟之后抽取随后的血液样品。通过商业上可获得的试剂盒确定葡萄糖(Diagnostic Chemicals Limited)和胰岛素(Alpco)的血浆水平。结果显示于图2A-D和3A-D中。
葡萄糖耐量试验
将雄性C57BL/6小鼠(在开始实验前已经用正常饮食(30g;ResearchDiets 12450)或高脂饮食(45g;Research Diets 12452)喂养12周)放在单独的笼子中并在12:12小时光:暗条件下维持,自由获得食物和水。麻醉小鼠并皮下植入渗透迷你泵(Alzet,Cupertino,CA)。该泵递送化合物A(剂量为200、600或1800nmole/kg/天)或载体14天。在第14天对小鼠禁食18小时或过夜。在第15天通过腹膜内向小鼠注射葡萄糖(2g/kg)进行葡萄糖耐量试验。葡萄糖注射后0、15、30、60和180分钟通过尾部穿刺采集血液样品,通过Accu-Chek血糖测计仪测量血糖水平。结果显示于图4中。
将雄性Lepob/Lepob小鼠(50g)分组存放并在12:12小时光:暗条件下维持,自由获得食物和水。小鼠禁食18小时或过夜并进行腹膜内葡萄糖耐量试验。在-15分钟对小鼠腹膜内注射化合物A(剂量为6.4μmole/kg),通过尾部穿刺采集血液样品。在时间0时对小鼠腹膜内注射葡萄糖(1g/kg),0、15、30、60和90分钟之后通过尾部穿刺采集血液样品,使用血糖测计仪Elite XL(Bayer Corporation)测量血糖水平。结果显示于图5中。
施用和用途
本发明的肽可以以可药用盐的形式提供。此类盐的实例包括,但不限于,用有机酸(例如,乙酸、乳酸、马来酸、柠檬酸、苹果酸、抗坏血酸、琥珀酸、苯甲酸、甲磺酸、甲苯磺酸或双羟萘酸)、无机酸(例如,盐酸、硫酸或磷酸)和聚合酸(如鞣酸、羧甲基纤维素、聚乳酸、聚乙醇酸或聚乳酸-乙醇酸共聚物)形成的盐。制备本发明肽的盐的典型方法是本领域公知的并且可以通过盐交换的标准方法完成。因此,通过将本发明的肽溶解在少量0.25N乙酸水溶液中,可以将本发明肽的TFA盐(通过使用制备HPLC用含有TFA的缓冲液洗脱纯化所述肽得到的TFA盐)转化成另一种盐,如乙酸盐。将所得的溶液应用于半制备HPLC柱(300SB,C-8)。将柱子用:(1)0.1N乙酸铵水溶液洗脱0.5小时;(2)0.25N乙酸水溶液洗脱0.5小时;和(3)线性梯度(30分钟内20%到100%溶液B)以4ml/分钟的流速洗脱(溶液A是0.25N乙酸水溶液;溶液B是乙腈/水(80∶20)中的0.25N乙酸)。收集合有所述肽的级分并冻干。
如本领域技术人员公知的,具有黑皮质素受体(MC-R)激动剂或拮抗剂活性的肽的已知和潜在用途是不同的和多样的,从而为了引起激动剂效果的目的,施用本发明的化合物可以具有与黑皮质素自身相同的效果和用途。
因此,本发明在其范围内包括药物组合物,其包含作为活性成分的至少一种通式(I)的化合物与可药用载体。
本发明组合物中的活性成分的剂量可以改变;然而,活性成分的量必须使得得到合适的剂型。所选的剂量依赖于所希望的治疗效果、施用途径、和治疗持续时间。通常,本发明活性的有效剂量为1x10-7到200mg/kg/天,优选1x10-4到100mg/kg/天,其可以作为单次剂量或者分成多次剂量施用。
本发明的化合物可以通过经口、肠胃外(例如,肌内、腹膜内、静脉内或皮下注射或植入)、经鼻、阴道、直肠、舌下或者局部施用途径施用并且可以与可药用载体配制以提供适于每种施用途径的剂型。
用于经口施用的固体剂型包括胶囊剂、片剂、丸剂、粉剂和粒剂。在此类固体剂型中,将活性化合物与至少一种惰性的可药用载体如蔗糖、乳糖或者淀粉混合。如此类剂型可以还包括(如常规实践)除了此类惰性稀释剂之外的额外物质,如润滑剂,如硬脂酸镁。对于胶囊剂、片剂和丸剂的情况,剂型还可以包含缓冲剂。可以额外用肠包衣制备片剂和丸剂。
用于经口施用的液体剂型包括可药用乳剂、溶液剂、混悬剂、糖浆剂、酏剂,其含有本领域常用的惰性稀释剂,如水。除了此类惰性稀释剂外,组合物可以还包括辅剂,如增湿剂、乳化和混悬剂,和增甜剂、调味剂和芳香剂。
用于肠胃外施用的根据本发明的制剂包括无菌水性或非水性溶液剂、混悬剂或乳剂。非水性溶剂或载体的实例是丙二醇、聚乙二醇、植物油,如橄榄油和玉米油、明胶和可注射的有机酯,如油酸乙酯。此类剂型还可以含有辅剂,如防腐剂、增湿剂、乳化剂和分散剂。通过例如经阻止细菌的滤器过滤、通过向组合物中掺入消毒剂,通过辐射组合物,或者通过加热组合物,可以对制剂消毒。也可以以无菌固体组合物的形式生产制剂,所述组合物可以临用前溶解在无菌水或者一些其他无菌可注射介质中。
用于直肠或阴道施用的组合物优选是栓剂,其除了活性物质外还可以含有赋形剂,如可可脂或栓剂蜡。
也可以用本领域公知的标准赋形剂制备用于经鼻或舌下施用的组合物。
此外,可以以如下面专利和专利申请中描述的那些以持续释放组合物的形式施用本发明的化合物。美国专利号5,672,659教导了包含生物活性剂和聚酯的持续释放组合物。美国专利号5,595,760教导了可胶化形式的包含生物活性剂的持续释放组合物。美国专利号5,821,221教导了包含生物活性剂和壳聚糖的聚合的持续释放组合物。美国专利号5,916,883教导了包含生物活性剂和环糊精的持续释放组合物。将前面专利和申请的教导通过引入本文作为参考。
序列表
<110>益普生制药股份有限公司
路易斯安那州州立大学及农业机械学院管理委员会
H·A·哈勒姆
M·D·库勒
A·A·巴特勒
<120>黑皮质素治疗胰岛素敏感的应用
<130>183P/PCT2
<150>US 61/001933
<151>2007-11-05
<160>293
<170>PatentIn version 3.5
<210>1
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC FEATURE
<222>(7)..(7)
<223>Xaa=β-Ala或者1-氨基-1-环己烷羧酸(A6c)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>1
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>2
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=6-氨基己酸(Ahx)或5-氨基戊酸(Apn)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>2
Xaa Cys His Xaa Arg Trp Xaa Cys
1 5
<210>3
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Ala,β-Ala或4-氨基丁酸(Gaba)
<220>
<221>MISC FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>3
Xaa Cys His Xaa Arg Trp Xaa Xaa Thr
1 5
<210>4
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>4
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>5
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的1-氨基-1-环己烷羧酸(A6c)
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>5
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>6
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal),β-环己基丙氨酸(Cha)或Nle,所有均用酰
基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>6
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>7
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala,β-丙氨酸,4-氨基丁酸(Gaba),α-氨基异丁酸(Aib)或Gly
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>7
Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>8
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=Ala,D-Ala,β-丙氨酸,4-氨基丁酸(Gaba),α-氨基异丁酸(Aib)或Gly
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>8
Xaa Xaa Xaa His Xaa Arg Trp Cys
1 5
<210>9
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala,β-丙氨酸,4-氨基丁酸(Gaba),α-氨基异丁酸(Aib)或Gly
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>9
Xaa Cys Xaa His Xaa Arg Trp Xaa
1 5
<210>10
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=Ala,D-Ala,β-丙氨酸,4-氨基丁酸(Gaba)或α-氨基异丁酸(Aib)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>10
Xaa Xaa Xaa His Xaa Arg Trp Xaa
1 5
<210>11
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=八氢吲哚-2-羧酸(Oic),环己基甘氨酸(Chg),高-环己基丙氨酸(hCha),
D-Cha,3-哌啶甲酸(Nip),hPro,hLeu,Phe,D-Phe,D-Chg,hPhe,beta-高Met,或4-氨基
丁酸(Gaba),所有均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>11
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>12
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用正丁酰基修饰的β-环己基丙氨酸(Cha)
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>12
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>13
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=β-环己基丙氨酸(Cha),高-环己基丙氨酸(hCha),Leu,
高-Leu(hLeu)或Phe,所有均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>13
Xaa Asp His Xaa Arg Xaa Ala Lys
1 5
<210>14
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=D-Ala,β-丙氨酸,4-氨基丁酸(Gaba),
7-氨基庚酸(Aha)or5-氨基戊酸(Apn)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>14
Xaa Asp His Xaa Arg Xaa Xaa Lys
1 5
<210>15
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn),4-氨基丁酸(Gaba),
6-氨基己酸(Ahx),β-丙氨酸,或D-Ala
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>15
Xaa Cys His Xaa Arg Xaa Xaa Cys
1 5
<210>16
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Trp,β-(2-萘基)丙氨酸(2-Nal)或β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>16
Xaa Cys Xaa His Xaa Arg Xaa Cys
1 5
<210>17
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用正丁酰基修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)或Trp
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>17
Xaa Cys Xaa His Xaa Arg Xaa Cys
1 5
<210>18
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal),β-(1-萘基)丙氨酸:(1-Nal)
或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>18
Xaa Cys Xaa His Xaa Arg Xaa Cys
1 5
<210>19
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=D-Ala
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>19
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>20
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-β-2-萘基丙氨酸(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>20
Xaa Cys Xaa His Xaa Arg Xaa Cys
1 5
<210>21
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>21
Xaa Xaa Xaa His Xaa Arg Trp Cys
1 5
<210>22
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=Cys或青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>22
Xaa Xaa Xaa His Xaa Arg Trp Xaa
1 5
<210>23
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>23
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr
1 5
<210>24
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=Arg或高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>24
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr
1 5
<210>25
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>25
Xaa Cys His Xaa Arg Xaa Xaa Xaa Thr
1 5
<210>26
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe或D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>26
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr
1 5
<210>27
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>27
Xaa Cys His Xaa Arg Trp Xaa Cys
1 5
<210>28
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Trp或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>28
Xaa Asp Xaa His Xaa Arg Xaa Lys
1 5
<210>29
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)或Cys
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>29
Xaa Cys Xaa His Xaa Arg Trp Xaa
1 5
<210>30
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-α-氨基丁酸(D-Abu),D-Val,D-Ile,D-Leu,
D-tert-Leu(D-Tle)或D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>30
Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>31
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>31
Xaa Xaa His Xaa Arg Trp Xaa Cys
1 5
<210>32
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=Cys或青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>32
Xaa Xaa His Xaa Arg Trp Xaa Xaa
1 5
<210>33
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Leu,β-环己基丙氨酸(Cha),Ile,Phe,Val或
β-(2-萘基)丙氨酸(2-Nal),所有均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>33
Xaa Cys His Xaa Arg Trp Xaa Cys
1 5
<210>34
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle或Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>34
Xaa Cys His Xaa Arg Trp Xaa Cys
1 5
<210>35
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=β-(3-吡啶基)丙氨酸(3-Pal)
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>35
Xaa Cys Xaa Xaa Arg Trp Xaa Cys
1 5
<210>36
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>36
Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>37
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>37
Xaa Cys His Phe Arg Xaa Xaa Cys
1 5
<210>38
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Ala或β-丙氨酸
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>38
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>39
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)或6-氨基己酸(Ahx)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>39
Xaa Cys His Xaa Arg Trp Xaa Cys
1 5
<210>40
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-Phe(hPhe)或β-环己基丙氨酸(Cha),都使用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>40
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>41
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-Ala或5-氨基戊酸(Apn)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>41
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>42
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=6-氨基己酸(Ahx)or5-氨基戊酸(Apn)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>42
Xaa Cys His Xaa Arg Trp Xaa Cys
1 5
<210>43
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Ala,β-Ala或4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MOD_RES
<222>(9)..(9)
<223>C末端是游离酸
<400>43
Xaa Cys His Xaa Arg Trp Xaa Xaa Thr
1 5
<210>44
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=β-环己基丙氨酸(Cha),Nle,环己基甘氨酸(Chg),D-Cha,
高-环己基丙氨酸(hCha),D-Chg或高-Phe(hPhe),所有均由酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>44
Xaa Asp His Xaa Arg Trp Xaa Lys
1 5
<210>45
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba),6-氨基己酸(Ahx),
β-Ala或D-Ala
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>45
Xaa Cys His Xaa Arg Xaa Xaa Cys
1 5
<210>46
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Trp,β-(2-萘基)丙氨酸(2-Nal),β-(1-萘基)丙氨酸:
(1-Nal)或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>46
Xaa Cys Xaa His Xaa Arg Xaa Cys
1 5
<210>47
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>47
Xaa Xaa Xaa His Xaa Arg Trp Cys
1 5
<210>48
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>C末端是游离酸
<400>48
Xaa Cys His Xaa Arg Trp Xaa Xaa
1 5
<210>49
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>49
Arg Cys Xaa His Xaa Arg Trp Cys
1 5
<210>50
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Arg或D-Arg,均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>50
Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>51
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Arg或Arg,均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>51
Xaa Cys Xaa His Xaa Arg Trp Xaa
1 5
<210>52
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Arg或Arg,均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>52
Xaa Cys His Xaa Arg Trp Xaa Xaa
1 5
<210>53
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Arg或Arg,均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>53
Xaa Asp His Xaa Arg Trp Ala Lys
1 5
<210>54
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=Gly,D-Ala,β-丙氨酸,4-氨基丁酸(Gaba)或
5-氨基戊酸(Apn)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>54
Xaa Cys Xaa His Xaa Arg Trp Xaa Cys
1 5
<210>55
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=Trp或β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>55
Cys Glu His Xaa Arg Xaa Ala Cys
1 5
<210>56
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=Trp或β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>56
Cys Xaa His Xaa Arg Xaa Ala Cys
1 5
<210>57
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=Ala,β-Ala或4-氨基丁酸(Gaba)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>57
Xaa Cys Xaa His Xaa Arg Trp Xaa Cys
1 5
<210>58
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>58
Xaa Asp Xaa His Xaa Arg Xaa Ala Lys
1 5
<210>59
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Glu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>59
Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>60
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(12)..(12)
<223>Xaa=Nle
<220>
<221>结构域
<222>(13)..(18)
<223>环状
<220>
<221>MISC_FEATURE
<222>(15)..(15)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>60
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Xaa Asp His Xaa Arg
1 5 10 15
Trp Lys
<210>61
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(12)..(12)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=Nle
<220>
<221>结构域
<222>(14)..(19)
<223>环状
<220>
<221>MISC_FEATURE
<222>(16)..(16)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>61
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Xaa Xaa Asp His Xaa
1 5 10 15
Arg Trp Lys
<210>62
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle或用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>62
Xaa Asp His Xaa Arg Trp Lys Xaa Tyr Gly Arg Lys Lys Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>63
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(8)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>63
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Lys Lys Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>64
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>64
Xaa Asp His Xaa Arg Trp Lys Pro Pro Lys Asp Tyr Gly Arg Lys Lys
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>65
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>65
Cys Glu His Xaa Arg Trp Gly Cys Pro Pro Lys Asp Tyr Gly Arg Lys
1 5 10 15
Lys Arg Arg Gln Arg Arg Arg
20
<210>66
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(8)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>66
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Lys Lys Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>67
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(12)..(12)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>67
Xaa Asp His Xaa Arg Trp Lys Pro Pro Lys Asp Xaa Tyr Gly Arg Lys
1 5 10 15
Lys Arg Arg Gln Arg Arg Arg
20
<210>68
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>68
Cys Glu His Xaa Arg Trp Gly Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Gln Arg Arg Arg
20
<210>69
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-Ala或8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>69
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Gln Arg Arg Arg
20
<210>70
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(8)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>70
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Lys Lys Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>71
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal),β-(1-萘基)丙氨酸:(1-Nal)
或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>71
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Gln Arg Arg Arg
20
<210>72
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>72
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>73
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>73
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Arg
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>74
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>74
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg
20
<210>75
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>75
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Gln Arg Arg Arg Arg
20
<210>76
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>76
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Gln Arg Arg Arg Arg Arg
20
<210>77
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>77
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Gln Lys Arg Arg Arg Arg Arg
20
<210>78
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>78
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Arg Arg Gln Arg
20
<210>79
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(15)..(15)
<223>Xaa=α-氨基异丁酸(Aib)
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>79
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Xaa Arg
1 5 10 15
Lys Lys Arg Arg Gln Arg Arg Arg
20
<210>80
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Arg或Lys
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>80
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>81
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)或β-(2-萘基)丙氨酸
(2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>81
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>82
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Arg或Lys
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>82
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>83
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Arg或Lys
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>83
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>84
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>84
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Arg Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>85
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>85
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Arg Gln Arg Arg
20
<210>86
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>86
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Gln Lys Lys Arg Arg Arg Arg Arg
20
<210>87
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>87
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Arg Arg Arg Gln
20
<210>88
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)或β-(2-萘基)丙氨酸
(2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>88
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Arg Lys
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>89
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>89
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Lys Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>90
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>90
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Lys Arg Arg Gln Arg Arg Arg
20
<210>91
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>91
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Arg
1 5 10 15
Lys Arg Arg Gln Arg Arg Arg
20
<210>92
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)或β-(1-萘基)丙氨酸:
(1-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>92
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Lys
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>93
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>93
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Arg Lys
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>94
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>94
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Lys Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>95
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>95
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Lys Arg Arg Gln Arg Arg Arg
20
<210>96
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>96
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Arg Arg Arg Gln Arg Arg Arg
20
<210>97
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>97
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Arg
1 5 10 15
Lys Arg Arg Gln Arg Arg Arg
20
<210>98
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>98
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Arg Lys
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>99
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>99
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Lys Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>100
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>100
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Lys Arg Arg Gln Arg Arg Arg
20
<210>101
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>101
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Arg Arg Arg Gln Arg Arg Arg
20
<210>102
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>102
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Arg
1 5 10 15
Lys Arg Arg Gln Arg Arg Arg
20
<210>103
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>103
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Lys
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>104
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>104
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Arg Lys
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>105
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>105
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Lys Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>106
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>106
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Gln Arg Arg Arg Arg
20
<210>107
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<22l>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>107
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Gln Arg Arg Arg Arg Arg
20
<210>108
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>108
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Gln Lys Arg Arg Arg Arg Arg
20
<210>109
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>109
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Gln Lys Lys Arg Arg Arg Arg Arg
20
<210>110
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>110
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Arg Gln Arg Arg
20
<210>111
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>111
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Arg Arg Gln Arg
20
<210>112
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>112
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15
Lys Lys Arg Arg Arg Arg Arg Gln
20
<210>113
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>113
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>114
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>114
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg
20
<210>115
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>115
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg Arg
20
<210>116
<211>25
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(25)..(25)
<223>酰胺化
<400>116
Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg Arg
20 25
<210>117
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>117
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>118
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>118
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg Arg
20
<210>119
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>119
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>120
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>120
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg
20
<210>121
<211>25
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(25)..(25)
<223>酰胺化
<400>121
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg Arg
20 25
<210>122
<211>25
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(1-萘基)丙氨酸:(1-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(25)..(25)
<223>酰胺化
<400>122
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Arg Gln Arg Arg Arg
20 25
<210>123
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>123
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>124
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>124
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>125
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>125
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg Arg
20
<210>126
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>126
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg
20
<210>127
<211>25
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(25)..(25)
<223>酰胺化
<400>127
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Arg Gln Arg Arg Arg
20 25
<210>128
<211>25
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(25)..(25)
<223>酰胺化
<400>128
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg Arg
20 25
<210>129
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>129
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>130
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>130
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg Arg
20
<210>131
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>131
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>132
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>132
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Arg
1 5 10 15
Arg Arg Arg Gln Arg Arg Arg
20
<210>133
<211>24
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(24)..(24)
<223>酰胺化
<400>133
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg
20
<210>134
<211>25
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(25)..(25)
<223>酰胺化
<400>134
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Gln Arg Arg Arg Arg
20 25
<210>135
<211>25
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Lys或Arg
<220>
<221>MISC_FEATURE
<222>(13)..(13)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(25)..(25)
<223>酰胺化
<400>135
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15
Arg Arg Arg Arg Arg Gln Arg Arg Arg
20 25
<210>136
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>136
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Lys Lys Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>137
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>137
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Tyr Gly Arg Lys Lys Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>138
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>138
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>139
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>139
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>140
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>140
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Gly Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>141
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>141
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Gly Arg Arg Lys Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>142
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>142
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Gly Arg Lys Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>143
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>143
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Arg Arg Lys Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>144
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>144
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Arg Lys Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>145
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>145
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Tyr Gly Arg Lys Lys Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>146
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>146
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Tyr Gly Arg Lys Lys Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>147
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>147
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>148
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>148
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>149
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>149
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Xaa Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>150
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>150
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>151
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>151
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>152
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>152
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Xaa Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>153
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>153
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg Arg
20
<210>154
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>154
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>155
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>155
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Xaa Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>156
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>156
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg Arg
20
<210>157
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>157
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>158
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=8-氨基-3,-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>158
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Xaa Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>159
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>159
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>160
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>160
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>161
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>161
Xaa Asp His Xaa Arg Trp Ala Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>162
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>162
Xaa Asp His Xaa Arg Trp Ala Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>163
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>163
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>164
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>164
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>165
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>165
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>166
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>166
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Gly Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>167
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>167
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>168
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>168
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>169
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>169
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg Arg
<210>170
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>170
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg Arg
20
<210>171
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>171
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>172
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>172
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg Arg
<210>173
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>173
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg Arg
20
<210>174
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(9)
<223>Xaa=8-氨基-3,6-氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>174
Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>175
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>175
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>176
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>176
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>177
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=6-氨基己酸(Ahx)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>177
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>178
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=6-氨基己酸(Ahx)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>178
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>179
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>179
Xaa Cys His Xaa Arg Trp Xaa Xaa Thr Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>180
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>180
Xaa Cys His Xaa Arg Trp Xaa Xaa Thr Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>181
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>181
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>182
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>182
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>183
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=β-环己基丙氨酸(Cha),高-环己基丙氨酸(hCha),或
Nle,所有均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>183
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>184
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=β-环己基丙氨酸(Cha)或高-环己基丙氨酸(hCha),均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>184
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>185
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle或环己基甘氨酸(Chg),均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>185
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>186
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=环己基甘氨酸(Chg)或高-环己基丙氨酸(hCha),均用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_ES
<222>(20)..(20)
<223>酰胺化
<400>186
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>187
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>187
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>188
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>188
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>189
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>189
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>190
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>190
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>191
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>191
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>192
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>192
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>193
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>193
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>194
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-环己基丙氨酸(hCha)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>194
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>195
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-环己基甘氨酸(D-Chg)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>195
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>196
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-环己基甘氨酸(D-Chg)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>196
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>197
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-phenylAla(hPhe)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>197
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>198
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=高-phenylAla(hPhe)用酰基(Ac)修饰
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>198
Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>199
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)或6-氨基己酸(Ahx)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>199
Xaa Cys His Xaa Arg Xaa Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>200
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)或6-氨基己酸(Ahx)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>200
Xaa Cys His Xaa Arg Xaa Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>201
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>201
Xaa Cys His Xaa Arg Xaa Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>202
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Trp
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>202
Xaa Cys His Xaa Arg Xaa Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>203
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>203
Xaa Cys Xaa His Xaa Arg Trp Xaa Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>204
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>204
Xaa Cys Xaa His Xaa Arg Trp Xaa Xaa Xaa Xaa Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>205
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>205
Xaa Cys Xaa His Xaa Arg Trp Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>206
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>206
Xaa Cys Xaa His Xaa Arg Trp Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>207
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>207
Xaa Cys Xaa His Xaa Arg Trp Xaa Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>208
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=青霉胺(Pen)
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>208
Xaa Cys Xaa His Xaa Arg Trp Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>209
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>209
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>210
<211>18
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(18)..(18)
<223>酰胺化
<400>210
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg
<210>211
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>211
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15
Arg Arg Arg
<210>212
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>212
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>213
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Gly或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>213
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>214
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>214
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Gly Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>215
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=Tyr或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>215
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Xaa Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>216
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>216
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>217
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>217
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>218
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>218
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>219
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>219
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>220
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>220
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>221
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>221
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>222
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>222
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg Arg
20
<210>223
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>223
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg Arg
20
<210>224
<211>23
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(23)..(23)
<223>酰胺化
<400>224
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg Arg
20
<210>225
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>225
Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg Arg
20
<210>226
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>226
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>227
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>227
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>228
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>228
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>229
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>229
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>230
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>230
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>231
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(11)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>231
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg
1 5 10 15
Arg Arg Gln Arg Arg Arg
20
<210>232
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=高-Arg(hArg)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=4,4’-联苯基丙氨酸(Bip)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(11)..(11)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>232
Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg
1 5 10 15
Gln Arg Arg Arg
20
<210>233
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>233
Xaa Cys Xaa His Xaa Arg Trp Gly Cys Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>234
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>234
Xaa Cys Xaa His Xaa Arg Trp Gly Cys Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>235
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>235
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>236
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>236
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>237
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>237
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>238
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>238
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>239
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>239
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>240
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>240
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>241
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>241
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>242
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=5-氨基戊酸(Apn)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>242
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>243
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>243
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>244
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>244
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>245
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>245
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>246
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>246
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>247
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>247
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>248
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>248
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>249
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>249
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>250
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Leu
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>250
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>251
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>251
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>252
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>252
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>253
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>253
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>254
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>254
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>255
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>255
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>256
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>256
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>257
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>257
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>258
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=用酰基(Ac)修饰的Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-环己基丙氨酸(D-Cha)
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>258
Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>259
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>259
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>260
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>260
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>261
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>261
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>262
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=β-Ala或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>262
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>263
<211>21
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(21)..(21)
<223>酰胺化
<400>263
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210>264
<211>19
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(19)..(19)
<223>酰胺化
<400>264
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg
<210>265
<211>22
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(22)..(22)
<223>酰胺化
<400>265
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15
Arg Gln Arg Arg Arg Arg
20
<210>266
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Nle
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=4-氨基丁酸(Gaba)
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)
<220>
<221>MISC_FEATURE
<222>(10)..(10)
<223>Xaa=8-氨基-3,6-二氧杂辛酸(Doc)或缺失
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>266
Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>267
<211>20
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Phe
<220>
<221>结构域
<222>(2)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-(Et)Tyr
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-丙氨酸
<220>
<221>MISC_FEATURE
<222>(8)..(8)
<223>Xaa=D-Cys
<220>
<221>MISC_FEATURE
<222>(9)..(10)
<223>Xaa=β-丙氨酸
<220>
<221>MOD_RES
<222>(20)..(20)
<223>酰胺化
<400>267
Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15
Arg Arg Arg Arg
20
<210>268
<211>12
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-4-bromo-phenylAla(D-4-Br-Phe)
<220>
<221>MOD_RES
<222>(12)..(12)
<223>酰胺化
<400>268
Cys Glu His Xaa Arg Trp Gly Cys Pro Pro Lys Asp
1 5 10
<210>269
<211>12
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=Trp,β-(2-萘基)丙氨酸(2-Nal),β-(1-萘基)丙氨酸:
(1-Nal)或3-苯并噻吩基丙氨酸(Bal)
<220>
<221>MOD_RES
<222>(12)..(12)
<223>酰胺化
<400>269
Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp
1 5 10
<210>270
<211>12
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用酰基(Ac)修饰
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)Ala(D-2-Nal)
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=β-(2-萘基)丙氨酸(2-Nal)
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=β-Ala或α-氨基异丁酸(Aib)
<220>
<221>MOD_RES
<222>(12)..(12)
<223>酰胺化
<400>270
Cys Glu His Xaa Arg Xaa Xaa Cys Pro Pro Lys Asp
1 5 10
<210>271
<211>7
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(7)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Cys或高半胱氨酸(hCys)
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(7)..(7)
<223>酰胺化
<400>271
Xaa Xaa His Xaa Arg Trp Cys
1 5
<210>272
<211>7
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(7)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Cys或高半胱氨酸(hCys)
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MOD_RES
<222>(7)..(7)
<223>酰胺化
<400>272
Xaa Xaa His Xaa Arg Trp Cys
1 5
<210>273
<211>7
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(7)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Lys,鸟氨酸(Orn),2,4-二氨基丁酸(Dab),或2,3-二氨基丙酸(Dap)
<220>
<221>MOD_RES
<222>(7)..(7)
<223>酰胺化
<400>273
Asp Xaa His Xaa Arg Trp Xaa
1 5
<210>274
<211>6
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(1)..(6)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=His,1-氨基-1-环丙烷羧酸(A3c),1-氨基-1-环戊烷羧酸(A5c),1-氨基-1-
环己烷羧酸(A6c),2-氨基茚-2-羧酸(Aic),或Apc
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(6)..(6)
<223>酰胺化
<400>274
Asp Xaa Xaa Arg Trp Lys
1 5
<210>275
<211>6
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(6)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=His,1-氨基-1-环丙烷羧酸(A3c),1-氨基-1-环戊烷羧酸(A5c),
1-氨基-1-环己烷羧酸(A6c),2-氨基茚-2-羧酸(Aic),或Apc
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MOD_RES
<222>(6)..(6)
<223>酰胺化
<400>275
Asp Xaa Xaa Arg Trp Lys
1 5
<210>276
<211>7
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(1)..(7)
<223>环状
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(7)..(7)
<223>Xaa=Lys,鸟氨酸(Orn),2,4-二氨基丁酸(Dab),或2,3-二氨基丙酸(Dap)
<220>
<221>MOD_RES
<222>(7)..(7)
<223>酰胺化
<400>276
Glu Xaa His Xaa Arg Trp Xaa
1 5
<210>277
<211>6
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(6)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(6)..(6)
<223>酰胺化
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=Lys或2,3-二氨基丙酸(Dap)
<400>277
Glu His Xaa Arg Trp Xaa
1 5
<210>278
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Arg,正亮氨酸(Nle),Gly,或D-Arg
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>278
Xaa Gly Cys Glu His Xaa Arg Trp Cys
1 5
<210>279
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=正亮氨酸(Nle),Gly,Ala,D-Ala,α-氨基异丁酸(Aib),Val,Ile,Leu,D-Arg,
或Arg
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>279
Xaa Gly Cys Xaa His Xaa Arg Trp Cys
1 5
<210>280
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=正亮氨酸(Nle)或Gly
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MISC_FEATURE
<222>(9)..(9)
<223>Xaa=青霉胺(Pen)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>280
Xaa Gly Cys Xaa His Xaa Arg Trp Xaa
1 5
<210>281
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=正亮氨酸(Nle)或Gly
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>281
Xaa Gly Cys Glu His Xaa Arg Trp Cys
1 5
<210>282
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=D-Arg或Arg
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>282
Xaa Gly Cys Xaa His Xaa Arg Trp Cys
1 5
<210>283
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Ala,Val,或Gly
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=正亮氨酸(Nle)
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>283
Xaa Xaa Cys Glu His Xaa Arg Trp Cys
1 5
<210>284
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=1-氨基-1-环己烷羧酸(A6c),Gly,Ala,D-Ala,Val,Leu,β-环己基丙氨酸
(Cha),或α-氨基异丁酸(Aib)
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=正亮氨酸(Nle)
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>284
Xaa Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>285
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe或D-β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>285
Gly Arg Cys Glu His Xaa Arg Trp Cys
1 5
<210>286
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe或D-β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>286
Gly Arg Cys Xaa His Xaa Arg Trp Cys
1 5
<210>287
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Arg
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>287
Gly Xaa Cys Glu His Xaa Arg Trp Cys
1 5
<210>288
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(2)..(2)
<223>Xaa=D-Arg
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe或D-β-(2-萘基)丙氨酸(D-2-Nal)
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>288
Gly Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>289
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=正亮氨酸(Nle)
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>289
Xaa Ala Cys Glu His Xaa Arg Trp Cys
1 5
<210>290
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=正亮氨酸(Nle),Ala,D-Ala,α-氨基异丁酸(Aib),Val,α-氨基丁酸
(Abu),Leu,Ile,β-环己基丙氨酸(Cha),1-氨基-1-环己烷羧酸acid(A6c),Phe,或Gly
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MISC_FEATURE
<222>(3)..(3)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>290
Xaa Cys Xaa His Xaa Arg Trp Cys
1 5
<210>291
<211>8
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(1)..(8)
<223>环状
<220>
<221>MOD_RES
<222>(1)..(1)
<223>用乙内酰脲(CO)修饰
<220>
<221>MISC_FEATURE
<222>(5)..(5)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(8)..(8)
<223>酰胺化
<400>291
Gly Cys Glu His Xaa Arg Trp Cys
1 5
<210>292
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>MISC_FEATURE
<222>(1)..(1)
<223>Xaa=Tyr,β-(2-萘基)丙氨酸(2-Nal),β-(1-萘基)丙氨酸:nine(1-Nal),Phe,
Trp,(S)-五氟苯丙氨酸(Pff),或His,所有均由酰基(Ac)修饰
<220>
<221>结构域
<222>(3)..(9)
<223>cylic
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>292
Xaa Arg Cys Xaa His Xaa Arg Trp Cys
1 5
<210>293
<211>9
<212>PRT
<213>人工序列
<220>
<223>治疗胰岛素敏感度的黑皮质素受体配体
<220>
<221>结构域
<222>(3)..(9)
<223>环状
<220>
<221>MISC_FEATURE
<222>(4)..(4)
<223>Xaa=D-Ala
<220>
<221>MISC_FEATURE
<222>(6)..(6)
<223>Xaa=D-Phe
<220>
<221>MOD_RES
<222>(9)..(9)
<223>酰胺化
<400>293
His Arg Cys Xaa His Xaa Arg Trp Cys
1 5
Claims (35)
1.一种治疗有其需要的受试者中胰岛素抵抗的方法,包括外周施用有效量的黑皮质素受体4激动剂以治疗所述有其需要的受试者之所述胰岛素抵抗。
2.根据权利要求1的方法,其中用于治疗胰岛素抵抗的所述的黑皮质素受体4激动剂选自:
Ac-Nle-c(Asp-His-D-Phe-Arg-Trpβ-Ala-Lys)-NH2;SEQ ID NO:1
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2;SEQ ID NO:1
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:2
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2;SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;SEQ ID NO:3
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:2
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;SEQ ID NO:4
Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:5
Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:6
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:10
Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
正丁酰基-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:12
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11
Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;SEQ ID NO:13
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2;SEQ ID NO:14
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2;SEQ ID NO:15
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2;SEQ ID NO:16
正丁酰基-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;SEQ IDNO:17
正丁酰基-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:17
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2;SEQ ID NO:18
Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:59
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;SEQ ID NO:19
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;SEQ ID NO:20
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:21
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:23
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:24
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:25
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:24
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ ID NO:26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;SEQ IDNO:26
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:27
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;SEQ ID NO:28
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;SEQ ID NO:29
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:30
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:31
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:32
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:33
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:34
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-OH;SEQ ID NO:36
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;SEQ ID NO:37
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2;SEQ ID NO:38
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:39
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:39
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:40
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH;SEQ ID NO:41
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;SEQ ID NO:42
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;SEQ ID NO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH;SEQ ID NO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;SEQ ID NO:43
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;SEQ ID NO:42
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;SEQ ID NO:41
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;SEQ ID NO:45
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;SEQ ID NO:46
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;SEQ ID NO:47
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH;SEQ ID NO:48
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;SEQ ID NO:49
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:51
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:52
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;SEQ ID NO:52
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:51
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:53
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;SEQ ID NO:53
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;SEQ ID NO:54
Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:55
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;SEQ ID NO:55
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:56
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;SEQ ID NO:56
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;SEQ ID NO:57
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2;SEQ ID NO:58
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;(SEQ ID NO:60)
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;(SEQ ID NO:61)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:62)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:62)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:63)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:64)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:65)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:66)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:67)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:68)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:69)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:70)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:72)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:73)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:74)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:75)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-Gln-(Arg)5-NH2;(SEQ ID NO:76)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-(Arg)5-NH2;(SEQ ID NO:77)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)4-Gln-Arg-NH2;(SEQ ID NO:78)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Aib-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:79)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:84)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)3-Gln-(Arg)2-NH2;(SEQ ID NO:85)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Gln-(Lys)2-(Arg)5-NH2;(SEQ ID NO:86)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)5-Gln-NH2;(SEQ ID NO:87)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:89)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:90)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:91)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:95)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:96)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:97)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:98)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:99)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:104)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:105)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:103)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:119)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:124)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:133)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:135)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-β-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;(SEQ ID NO:135)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;(SEQ ID NO:137)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:139)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:140)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:141)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-β-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;(SEQ ID NO:143)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;(SEQ ID NO:144)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:149);
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:158)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:159)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:160)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:161)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:162)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Ph e-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:175)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:176)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:177)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:178)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:179)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:180)
Ac-Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:181)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:182)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:183)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:184)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:183)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:185)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:186)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:185)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:186)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:187)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:194)
Ac-D-Chg-c(Asp-His-D-Ph e-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:195)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:196)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:197)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:198)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:201)
Ac-Nle-c(Cys-His-D-Ph e-Arg-D-Trp-β-Ala-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:202)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-la-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Pen)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:208)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:210)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:211)
D-Ph e-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:212)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:267)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:217)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:220)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:226)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:227)
D-Ph e-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:229)
D-Ph e-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:230)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:232)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:231)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:232)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:233)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:234)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:238)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:239)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:240)
Nle-c(Cys-His-D-Ph e-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:242)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:243)
Ac-Nle-c(Cys-D-Leu-His-D-Ph e-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:245)
Ac-Nle-c(Cys-D-Leu-His-D-Ph e-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:250)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;_(SEQ ID NO:253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;_(SEQ ID NO:257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:258)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;(SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;(SEQ ID NO:266)
Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:268)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQID NO:210)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-β-Ala-Cys)-(Pro)2-Lys-Asp-NH2;(SEQ ID NO:270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-(Pro)2-Lys-Asp-NH2;(SEQID NO:270)
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ IDNO:271)
c[乙内酰脲(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ IDNO:271)
c[乙内酰脲(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;(SEQ IDNO:272)
c[乙内酰脲(C(O)-(hCys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;(SEQ IDNO:272)
c [乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2;(SEQ IDNO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;(SEQ IDNO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;(SEQ IDNO:273)
c[乙内酰脲(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;(SEQ IDNO:273)
c[乙内酰脲(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ ID NO:274)
c[乙内酰脲(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ ID NO:274)
c[乙内酰脲(C(O)-(Asp-A5c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ ID NO:274)
c[乙内酰脲(C(O)-(Asp-A6c))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ ID NO:274)
c[乙内酰脲(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-Aic))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ ID NO:274)
c[乙内酰脲(C(O)-(Asp-Apc))-D-Phe-Arg-Trp-Lys]-NH2;(SEQ ID NO:274)
c[乙内酰脲(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;(SEQ IDNO:275)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;(SEQ IDNO:276)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;(SEQ IDNO:276)
c[乙内酰脲(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;(SEQ IDNO:276)
c[乙内酰脲(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH2;(SEQ IDNO:277)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQID NO:278)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQID NO:278)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
乙内酰脲(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:281)
乙内酰脲(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:281)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:278)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
乙内酰脲(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:282)
乙内酰脲(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:282)
乙内酰脲(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQID NO:283)
乙内酰脲(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQID NO:283)
乙内酰脲(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQID NO:283)
乙内酰脲(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:285)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:285)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:286)
乙内酰脲(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:286)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:287)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:288)
乙内酰脲(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;(SEQ ID NO:288)
乙内酰脲(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQID NO:289)
c[乙内酰脲(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2,(SEQID NO:290)
c[乙内酰脲(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[乙内酰脲(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c [乙内酰脲(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ IDNO:290)
c[乙内酰脲(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQID NO:290)
c[乙内酰脲(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ IDNO:291)
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ IDNO:292)
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:292)
H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:293)
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:292)
或其可药用盐。
3.根据权利要求2的方法,其中所述化合物是Ac-Arg-c(Cys-D-Ala-His-D-Ph e-Arg-Trp-Cys)-NH2(SEQ ID NO:50)或其可药用盐。
4.根据权利要求2的方法,其中所述化合物是乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ IDNO:278)或其可药用盐。
5.根据权利要求1-4任一项的方法,其中所述受试者是肥胖的。
6.根据权利要求1-4任一项的方法,其中所述受试者是超重的。
7.根据权利要求1-4任一项的方法,其中所述受试者是正常体重的。
8.根据权利要求1-4任一项的方法,其中所述的受试者是偏瘦的。
9.根据权利要求5的方法,其中所述肥胖的受试者罹患II型糖尿病。
10.根据权利要求6的方法,其中所述超重的受试者罹患II型糖尿病。
11.根据权利要求7的方法,其中所述正常体重的受试者罹患II型糖尿病。
12.根据权利要求8的方法,其中所述偏瘦的受试者罹患II型糖尿病。
13.根据权利要求1的方法,其中所述外周施用是经口、皮下、腹膜内、肌内、静脉内、直肠、经皮或鼻内。
14.根据权利要求13的方法,其中所述施用是连续的、每小时的、每天四次、每天三次、每天两次、每天一次、每隔一天一次、每周两次、每周一次、每两周一次、每月一次,或每两月一次。
15.根据权利要求14的方法,其中所述施用是连续的。
16.根据权利要求14的方法,其中所述施用是每天一次。
17.根据权利要求14的方法,其中所述施用是每周一次。
18.根据权利要求14的方法,其中所述施用是每两周一次。
19.根据权利要求14的方法,其中所述施用是每月一次。
20.根据权利要求14的方法,其中所述施用是每两月一次。
21.根据权利要求1-4任一项的方法,其中所述外周施用有效量的黑皮质素受体4激动剂以治疗有其需要的受试者之所述胰岛素抵抗也降低所述有其需要的受试者之体重。
22.根据权利要求21的方法,其中所述化合物是Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ ID NO:50)或其可药用盐。
23.根据权利要求21的方法,其中所述化合物是乙内酰脲(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2(SEQ IDNO:278)或其可药用盐。
24.根据权利要求21-23任一项的方法,其中所述受试者是肥胖的。
25.根据权利要求21-23任一项的方法,其中所述受试者是超重的。
26.根据权利要求24的方法,其中所述肥胖的受试者罹患II型糖尿病。
27.根据权利要求25的方法,其中所述超重的受试者罹患II型糖尿病。
28.根据权利要求21的方法,其中所述外周施用是经口、皮下、腹膜内、肌内、静脉内、直肠、经皮或鼻内。
29.根据权利要求28的方法,其中所述的施用是连续的、每小时的、每天四次、每天三次、每天两次、每天一次、每隔一天一次、每周两次、每周一次、每两周一次、每月一次,或每两月一次。
30.根据权利要求29的方法,其中所述施用是连续的。
31.根据权利要求29的方法,其中所述施用是每天一次。
32.根据权利要求29的方法,其中所述施用是每周一次。
33.根据权利要求29的方法,其中所述施用是每两周一次。
34.根据权利要求29的方法,其中所述施用是每月一次。
35.根据权利要求29的方法,其中所述施用是每两月一次。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310178847.4A CN103316345B (zh) | 2007-11-05 | 2008-11-05 | 黑皮质素治疗胰岛素敏感的应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US193307P | 2007-11-05 | 2007-11-05 | |
US61/001,933 | 2007-11-05 | ||
PCT/US2008/012490 WO2009061411A2 (en) | 2007-11-05 | 2008-11-05 | Use melanocortins to treat insulin sensitivity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310178847.4A Division CN103316345B (zh) | 2007-11-05 | 2008-11-05 | 黑皮质素治疗胰岛素敏感的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101980717A true CN101980717A (zh) | 2011-02-23 |
Family
ID=40626385
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801238931A Pending CN101980717A (zh) | 2007-11-05 | 2008-11-05 | 黑皮质素治疗胰岛素敏感的应用 |
CN201310178847.4A Active CN103316345B (zh) | 2007-11-05 | 2008-11-05 | 黑皮质素治疗胰岛素敏感的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310178847.4A Active CN103316345B (zh) | 2007-11-05 | 2008-11-05 | 黑皮质素治疗胰岛素敏感的应用 |
Country Status (21)
Country | Link |
---|---|
US (6) | US9155777B2 (zh) |
EP (2) | EP2979703B1 (zh) |
JP (3) | JP2011502987A (zh) |
KR (3) | KR20150013339A (zh) |
CN (2) | CN101980717A (zh) |
AR (1) | AR069461A1 (zh) |
AU (1) | AU2008325194B2 (zh) |
BR (1) | BRPI0819188B1 (zh) |
CA (2) | CA2952095C (zh) |
DK (1) | DK2214693T3 (zh) |
ES (2) | ES2690556T3 (zh) |
HK (3) | HK1146242A1 (zh) |
HU (1) | HUE026842T2 (zh) |
IL (2) | IL205554A (zh) |
NZ (1) | NZ585131A (zh) |
PL (1) | PL2214693T3 (zh) |
PT (2) | PT2979703T (zh) |
RU (1) | RU2453328C2 (zh) |
TR (1) | TR201815292T4 (zh) |
TW (1) | TWI374030B (zh) |
WO (1) | WO2009061411A2 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2689016C (en) * | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
RU2453328C2 (ru) | 2007-11-05 | 2012-06-20 | Ипсен Фарма С.А.С. | Применение меланокортинов для лечения чувствительности к инсулину |
WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
KR101726893B1 (ko) | 2009-06-08 | 2017-04-13 | 팔라틴 테크놀로지스 인코포레이티드 | 멜라노코르틴 수용체-특이적 펩티드 |
RU2012108110A (ru) * | 2009-08-05 | 2013-09-10 | Ипсен Фарма С.А.С. | Применение меланокортинов для лечения дислипидемии |
HUE031856T2 (en) * | 2009-08-31 | 2017-08-28 | Tensive Controls Inc | Stabilized melanocortin ligands |
RU2548753C2 (ru) | 2009-11-16 | 2015-04-20 | Ипсен Фарма С.А.С. | Фармацевтические композиции лигандов рецепторов меланокортинов |
EP2504351A4 (en) | 2009-11-23 | 2013-10-30 | Palatin Technologies Inc | MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE |
MX2012005862A (es) | 2009-11-23 | 2012-09-07 | Palatin Technologies Inc | Peptidos ciclicos especificos del receptor de melanocortina-1. |
WO2012172433A2 (en) * | 2011-06-14 | 2012-12-20 | Ipsen Pharma S.A.S. | A sustained-release composition containing peptides as active ingredient |
HRP20211950T1 (hr) | 2011-12-29 | 2022-03-18 | Rhythm Pharmaceuticals, Inc. | Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima |
US9534018B2 (en) | 2012-03-13 | 2017-01-03 | Tensive Controls Inc. | Melanocortin analogs having enhanced activity and transport |
RU2019116003A (ru) | 2013-03-15 | 2019-07-17 | Ритм Фармасьютикалз, Инк. | Фармацевтические композиции |
CN118240012A (zh) | 2013-03-15 | 2024-06-25 | 节奏制药公司 | 肽组合物 |
US10314883B2 (en) | 2015-02-13 | 2019-06-11 | University Of Virginia Patent Foundation | Compositions and methods for regulating blood pressure |
WO2017019952A1 (en) | 2015-07-29 | 2017-02-02 | University Of Virginia Patent Foundation | Compositions and methods for regulating leukocyte adhesion |
WO2017049140A2 (en) | 2015-09-18 | 2017-03-23 | Wake Forest University Health Sciences | Angiotensin (1-7) analogs and methods relating thereto |
US11124541B2 (en) * | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
CA3102603A1 (en) | 2018-06-05 | 2019-12-12 | The Research Foundation For The State University Of New York | Method for passive wireless channel estimation in radio frequency network and apparatus for same |
US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784423A (zh) * | 2003-05-09 | 2006-06-07 | 诺沃挪第克公司 | 用于治疗肥胖的肽 |
WO2007008704A2 (en) * | 2005-07-08 | 2007-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Melanocortin receptor ligands |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
MXPA03002160A (es) | 2000-09-13 | 2004-05-04 | Eleanor Roosevelt Inst | Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes. |
US7034033B2 (en) * | 2002-05-23 | 2006-04-25 | Chiron Corporation | Substituted quinazolinone compounds |
DE60313844T2 (de) * | 2003-03-20 | 2008-01-31 | Santhera Pharmaceuticals (Schweiz) Ag | Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren |
JP2006521359A (ja) | 2003-03-26 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体作働薬としての二環式ピペリジン誘導体 |
KR20060026011A (ko) * | 2003-05-09 | 2006-03-22 | 노보 노르디스크 에이/에스 | 비만 치료용 펩티드 |
JP2007524584A (ja) | 2003-05-09 | 2007-08-30 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療に使用するペプチド |
WO2005000339A2 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(mc4) agonists and their uses |
US20070123453A1 (en) * | 2004-03-29 | 2007-05-31 | Heiman Mark L | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion |
WO2006049933A2 (en) * | 2004-10-29 | 2006-05-11 | Merck & Co., Inc. | Compositions and methods for the treatment of obesity and sexual dysfunction |
WO2007008684A2 (en) | 2005-07-08 | 2007-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Ligands of melanocortin receptors |
EP1951212A2 (en) | 2005-11-22 | 2008-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
CA2689016C (en) * | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
EP2167112A4 (en) * | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
RU2453328C2 (ru) * | 2007-11-05 | 2012-06-20 | Ипсен Фарма С.А.С. | Применение меланокортинов для лечения чувствительности к инсулину |
RU2012108110A (ru) | 2009-08-05 | 2013-09-10 | Ипсен Фарма С.А.С. | Применение меланокортинов для лечения дислипидемии |
-
2008
- 2008-11-05 RU RU2010122897/15A patent/RU2453328C2/ru active
- 2008-11-05 ES ES15179111.8T patent/ES2690556T3/es active Active
- 2008-11-05 EP EP15179111.8A patent/EP2979703B1/en active Active
- 2008-11-05 BR BRPI0819188-3A patent/BRPI0819188B1/pt active IP Right Grant
- 2008-11-05 KR KR1020147036380A patent/KR20150013339A/ko not_active Application Discontinuation
- 2008-11-05 DK DK08846334.4T patent/DK2214693T3/en active
- 2008-11-05 CA CA2952095A patent/CA2952095C/en active Active
- 2008-11-05 AR ARP080104846A patent/AR069461A1/es unknown
- 2008-11-05 EP EP08846334.4A patent/EP2214693B1/en active Active
- 2008-11-05 HU HUE08846334A patent/HUE026842T2/en unknown
- 2008-11-05 ES ES08846334.4T patent/ES2555522T3/es active Active
- 2008-11-05 WO PCT/US2008/012490 patent/WO2009061411A2/en active Application Filing
- 2008-11-05 PT PT15179111T patent/PT2979703T/pt unknown
- 2008-11-05 CN CN2008801238931A patent/CN101980717A/zh active Pending
- 2008-11-05 KR KR1020137011647A patent/KR101662044B1/ko active IP Right Grant
- 2008-11-05 PL PL08846334T patent/PL2214693T3/pl unknown
- 2008-11-05 KR KR1020107012327A patent/KR101290623B1/ko active IP Right Grant
- 2008-11-05 CN CN201310178847.4A patent/CN103316345B/zh active Active
- 2008-11-05 TW TW097142727A patent/TWI374030B/zh active
- 2008-11-05 PT PT88463344T patent/PT2214693E/pt unknown
- 2008-11-05 US US12/740,917 patent/US9155777B2/en active Active
- 2008-11-05 TR TR2018/15292T patent/TR201815292T4/tr unknown
- 2008-11-05 JP JP2010532076A patent/JP2011502987A/ja active Pending
- 2008-11-05 NZ NZ585131A patent/NZ585131A/xx unknown
- 2008-11-05 CA CA2704651A patent/CA2704651C/en active Active
- 2008-11-05 AU AU2008325194A patent/AU2008325194B2/en active Active
-
2010
- 2010-05-05 IL IL205554A patent/IL205554A/en active IP Right Grant
-
2011
- 2011-01-19 HK HK11100510.8A patent/HK1146242A1/zh unknown
-
2013
- 2013-02-28 JP JP2013038619A patent/JP5964767B2/ja active Active
- 2013-10-29 HK HK13112170.2A patent/HK1184692A1/zh unknown
-
2015
- 2015-02-26 JP JP2015036512A patent/JP2015131827A/ja active Pending
- 2015-09-03 US US14/844,128 patent/US9439943B2/en active Active
-
2016
- 2016-08-02 HK HK16109223.2A patent/HK1221147A1/zh unknown
- 2016-08-22 US US15/242,866 patent/US9827286B2/en active Active
-
2017
- 2017-01-09 IL IL249998A patent/IL249998B/en active IP Right Grant
- 2017-11-02 US US15/801,432 patent/US20180303899A1/en not_active Abandoned
-
2018
- 2018-12-19 US US16/225,189 patent/US20190111105A1/en not_active Abandoned
-
2022
- 2022-06-03 US US17/831,887 patent/US20220339239A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784423A (zh) * | 2003-05-09 | 2006-06-07 | 诺沃挪第克公司 | 用于治疗肥胖的肽 |
WO2007008704A2 (en) * | 2005-07-08 | 2007-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Melanocortin receptor ligands |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101980717A (zh) | 黑皮质素治疗胰岛素敏感的应用 | |
CN101257916B (zh) | 黑皮质素受体配体 | |
CN101528250A (zh) | 黑皮质素受体的配体 | |
US7084111B2 (en) | Melanocortin receptor templates, peptides, and use thereof | |
CN102548399A (zh) | 黑皮质素治疗血脂异常的用途 | |
KR20070031440A (ko) | 카켁시아 치료용 시클릭 펩타이드 | |
KR20070032054A (ko) | 카켁시아 치료용 시클릭 펩타이드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110223 |